var title_f26_53_27472="Femoral anatomy child";
var content_f26_53_27472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the femur in the child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration depicts the anatomy of the femur in the child. The epiphyses appear as blue shaded regions and the physes as salmon shaded areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27472=[""].join("\n");
var outline_f26_53_27472=null;
var title_f26_53_27473="Calculator: Glomerular filtration rate estimate by CKD-EPI equation";
var content_f26_53_27473=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"GFR_CKD_EPI_form\" name=\"GFR_CKD_EPI_form\" onkeydown=\"clrResults();\" onkeyup=\"GFR_CKD_EPI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Glomerular filtration rate estimate by CKD-EPI equation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          GFR = 141 * min(SerumCreat/kappa, 1)",
"          <sup>",
"           alpha",
"          </sup>",
"          * max(SerumCreat/kappa, 1)",
"          <sup>",
"           -1.209",
"          </sup>",
"          * 0.993",
"          <sup>",
"           Age",
"          </sup>",
"          * Sex * Race",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\" nowrap=\"nowrap\">",
"             <span class=\"medCalcFontCCTab\">",
"              &nbsp;&nbsp;",
"Female",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"Sex = 1.018; alpha = -0.329; kappa = 0.7; GFR_CKD_EPI_fx();\" type=\"radio\" value=\"Female\"/>",
"              &nbsp;&nbsp;&nbsp;&nbsp;",
"Male",
"              <input name=\"Sex_radio\" onclick=\"Sex = 1; alpha = -0.411; kappa = 0.9;; GFR_CKD_EPI_fx();\" type=\"radio\" value=\"Male\"/>",
"              &nbsp;&nbsp;&nbsp;",
"              <br/>",
"              &nbsp;",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Race",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Race_radio\" onclick=\"GFR_CKD_EPI_fx();\" type=\"radio\" value=\"White or Other|1\"/>",
"              White or Other (1)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Race_radio\" onclick=\"GFR_CKD_EPI_fx();\" type=\"radio\" value=\"Black|1.159\"/>",
"              Black (1.159)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"GFR_CKD_EPI_fx(); minMaxCheck();\" onchange=\"GFR_CKD_EPI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"GFR_CKD_EPI_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Creat_param\" onblur=\"GFR_CKD_EPI_fx(); minMaxCheck();\" onchange=\"GFR_CKD_EPI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Creat_unit\" onchange=\"GFR_CKD_EPI_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0113122171945701|0|mcmol/L_Cr\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1|0|mg%_Cr\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Cr\">",
"               mg/dL",
"              </option>",
"              <option value=\"11.3122171945701|0|mmol/L_Cr\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              GFR",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"GFR_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                mL/min/1.73m",
"                <sup>",
"                 2",
"                </sup>",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"GFR_CKD_EPI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       GFR is estimated by an equation developed by the Chronic Kidney Disease Epidemiology Collaboration.",
"      </li>",
"      <li>",
"       For females, the following values are used: Sex = 1.018; alpha = -0.329; kappa = 0.7",
"      </li>",
"      <li>",
"       For males, the following values are used: Sex = 1; alpha = -0.411; kappa = 0.9",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      Race",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g.  (1), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Levey AS, Stevens LA, Schmid CH, et. al. for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).  A New Equation to Estimate Glomerular Filtration Rate.",
"        <i>",
"         Ann Intern Med",
"        </i>",
"        . 2009 May 5;150(9):604-612.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
"with(document.GFR_CKD_EPI_form){",
"Sex = 1.018; alpha = -0.329; kappa = 0.7;",
"",
"}",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27473=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function GFR_CKD_EPI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.GFR_CKD_EPI_form){",
"",
"",
"doCalc = true;",
"if (Race_radio[0].checked){ Race = 1; }",
"if (Race_radio[1].checked){ Race = 1.159; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Creat_param.value.indexOf(',') >= 0){ Serum_Creat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Creat_unit.options[Serum_Creat_unit.selectedIndex].value.split('|');",
"Serum_Creat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"GFR =  141 * power(Math.min(Serum_Creat/kappa, 1), alpha) * power(Math.max(Serum_Creat/kappa, 1), -1.209) * power(0.993,Age) * Sex * Race;",
"",
"if (doCalc) GFR_param.value = fixDP(GFR, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GFR_CKD_EPI_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GFR_CKD_EPI_form){",
"",
"GFR_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"var alpha;",
"",
"var kappa;",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f26_53_27473=null;
var title_f26_53_27474="Takayasu arteritis aneurysm 1";
var content_f26_53_27474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusiform aneurysm and wall thickening in a patient with Takayasu arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlargement of the descending thoracic aorta and thickening of the vessel wall (arrows) is apparent in this contrast enhanced CT scan. These findings suggest an active inflammatory process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. Am J Roentgenology 2000; 175:1727. Copyright &copy; 2000 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27474=[""].join("\n");
var outline_f26_53_27474=null;
var title_f26_53_27475="Patient information: Paraplegia and quadriplegia (The Basics)";
var content_f26_53_27475=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17207\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"         Anatomy of the back",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/12/23746\">",
"         Patient information: Chronic pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/16/34050\">",
"         Patient information: Going home from the hospital (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/31/40447\">",
"         Patient information: Multiple sclerosis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/0/15363\">",
"         Patient information: Neck fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/58/35746\">",
"         Patient information: Osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/53/39761\">",
"         Patient information: Pressure sores (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/47/20210\">",
"         Patient information: Urinary tract infections in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/49/25366\">",
"         Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/33/29205\">",
"         Patient information: Sexual problems in men (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/18/32036\">",
"         Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Paraplegia and quadriplegia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/paraplegia-and-quadriplegia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15744895\">",
"      <span class=\"h1\">",
"       What are paraplegia and quadriplegia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Paraplegia is the term doctors use when people can&rsquo;t move their legs, but can move their arms. Quadriplegia is the term doctors use when people can&rsquo;t move their arms or legs.",
"     </p>",
"     <p>",
"      The most common cause of paraplegia and quadriplegia is an injury to the spinal cord. The spinal cord is the bundle of nerves that runs down a person&rsquo;s back (",
"      <a class=\"graphic graphic_figure graphicRef56246 \" href=\"UTD.htm?4/51/4917\">",
"       figure 1",
"      </a>",
"      ). Certain nerve disorders, such as multiple sclerosis, can also cause paraplegia and quadriplegia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15744910\">",
"      <span class=\"h1\">",
"       What other symptoms can people with paraplegia or quadriplegia have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Besides being unable to move part of their body, people might also have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        No feeling in the arms or legs",
"       </li>",
"       <li>",
"        No control over their bladder or bowel",
"       </li>",
"       <li>",
"        Trouble breathing &ndash; This can happen only with quadriplegia.",
"       </li>",
"       <li>",
"        Sex problems, including trouble getting an erection or ejaculating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15744925\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People with paraplegia or quadriplegia have tests to see what&rsquo;s causing their condition and how serious their condition is. Different tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        X-rays",
"       </li>",
"       <li>",
"        Imaging tests, such as a CT or MRI scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        Nerve tests to check whether the nerves are working normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15744940\">",
"      <span class=\"h1\">",
"       How are paraplegia and quadriplegia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for paraplegia and quadriplegia involves treatment right after the spinal cord injury plus long-term treatment.",
"     </p>",
"     <p>",
"      Right after a spinal cord injury, people are treated in the hospital. There, the doctor can monitor them and treat the medical problems that happen. For instance, people who are having a very hard time breathing usually need a breathing tube. A breathing tube is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing.",
"     </p>",
"     <p>",
"      Some people with a spinal cord injury are treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines called steroids &ndash; These are different from the steroids athletes take to build muscle. These steroids help reduce swelling in the spinal cord.",
"       </li>",
"       <li>",
"        Surgery to fix the back bones (vertebrae), if they got pushed out of position",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Long-term treatment involves different parts. The main part is called &ldquo;rehab.&rdquo; Rehab is a term for the care people get after an injury. In rehab, doctors, nurses, and other health professionals will teach you how to be as independent as possible and stay as healthy as possible. This includes how to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a wheelchair",
"       </li>",
"       <li>",
"        Manage your bladder and bowel, if you have no control over your bladder or bowel",
"       </li>",
"       <li>",
"        Exercise, so that you can regain as much movement in your arms or legs as possible",
"       </li>",
"       <li>",
"        Cope with feelings of sadness or anger",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another big part of long-term treatment is helping prevent problems that commonly happen in people with paraplegia or quadriplegia. These problems can happen when people sit or lie in the same position for a very long time. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Urinary tract infections and kidney problems",
"       </li>",
"       <li>",
"        Pressure sores, which are areas of damage to the skin and tissue under the skin caused by pressure",
"       </li>",
"       <li>",
"        Lung infections and breathing problems",
"       </li>",
"       <li>",
"        Osteoporosis, which is a disease that makes your bones weak",
"       </li>",
"       <li>",
"        Muscle and joint stiffness",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will show you ways to prevent and manage these problems. This might include changing your body position often or sleeping on a special type of mattress.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15744955\">",
"      <span class=\"h1\">",
"       What will my life be like with paraplegia or quadriplegia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with paraplegia or quadriplegia lead a full life. Many people are able to work, drive, have serious relationships, and have children. Some people even regain some movement or feeling in their arms or legs.",
"     </p>",
"     <p>",
"      Many people with paraplegia or quadriplegia worry about whether they will be able to have sex. Problems with sex are common, but there are medicines and devices that can often help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15744970\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"       Patient information: Neck fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=see_link\">",
"       Patient information: Multiple sclerosis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/53/39761?source=see_link\">",
"       Patient information: Pressure sores (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       Patient information: Osteoporosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23746?source=see_link\">",
"       Patient information: Chronic pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20210?source=see_link\">",
"       Patient information: Urinary tract infections in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=see_link\">",
"       Patient information: Going home from the hospital (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"       Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       Patient information: Sexual problems in men (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/53/27475?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17207 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27475=[""].join("\n");
var outline_f26_53_27475=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15744895\">",
"      What are paraplegia and quadriplegia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15744910\">",
"      What other symptoms can people with paraplegia or quadriplegia have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15744925\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15744940\">",
"      How are paraplegia and quadriplegia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15744955\">",
"      What will my life be like with paraplegia or quadriplegia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15744970\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4917\">",
"      Anatomy of the back",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23746?source=related_link\">",
"      Patient information: Chronic pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=related_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/53/39761?source=related_link\">",
"      Patient information: Pressure sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=related_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20210?source=related_link\">",
"      Patient information: Urinary tract infections in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_53_27476="Vaginal cuff brachythr apps";
var content_f26_53_27476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal cuff brachytherapy applicators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vaginal ovoids (A) and vaginal cylinders (B) for vaginal cuff brachytherapy for endometrial cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27476=[""].join("\n");
var outline_f26_53_27476=null;
var title_f26_53_27477="Naltrexone: Patient drug information";
var content_f26_53_27477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Naltrexone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     see \"Naltrexone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ReVia&reg;;",
"     </li>",
"     <li>",
"      Vivitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ReVia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep an alcohol-free state.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691410",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep a drug-free state.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to naltrexone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Hepatitis or liver failure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are addicted to drugs or are having withdrawal signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a pain drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral and shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10889 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27477=[""].join("\n");
var outline_f26_53_27477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199546\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199547\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013425\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013427\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013426\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013431\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013432\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013434\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013429\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013430\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013435\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013436\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=related_link\">",
"      Naltrexone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_53_27478="Cholera cots";
var content_f26_53_27478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cholera cots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These devices, in which patients may defecate directly into a collection bucket, facilitate the rapid measurement of ongoing fluid losses and management of epidemics. Inexpensive hand decontamination between examinations may be facilitated by using a portable locally prepared hand sanitizer with at least 60 percent ethanol or isopropenol and an emollient such as 3 percent glycerol",
"    <sup>",
"     [1]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Boyce, JM, Pittet, D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1,45, quiz CE1-4.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27478=[""].join("\n");
var outline_f26_53_27478=null;
var title_f26_53_27479="Advanced case 2";
var content_f26_53_27479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1055px;\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Advanced case 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27479=[""].join("\n");
var outline_f26_53_27479=null;
var title_f26_53_27480="The incompatible crossmatch";
var content_f26_53_27480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The incompatible crossmatch",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Dennis Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Qun Lu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27480/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/53/27480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An essential goal in transfusion medicine is that transfused blood be compatible with the patient. The clinical and serologic evaluation, which allows for the transfusion of the most compatible (or \"least incompatible\") blood, requires a joint effort between the clinician and the transfusion medicine physician [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are times when all available resources are exhausted and a unit of blood that is not crossmatch compatible must be issued to the patient. The most common of these clinical situations as well as suggestions on how safely to issue and transfuse the best unit of blood available will be reviewed here. General discussions of crossmatching procedures and red cell antigens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link\">",
"     \"Compatibility testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link\">",
"     \"A primer of red blood cell antigens and antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CROSSMATCHING OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;When blood is ordered for transfusion, the transfusion service typically performs a series of tests on the patient's red cells and plasma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sample of blood is obtained from the patient and the ABO and Rh types are determined on",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      red cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link&amp;anchor=H5#H5\">",
"       \"Compatibility testing\", section on 'Specimen requirements'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient's plasma is then screened for the presence of unexpected antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link&amp;anchor=H6#H6\">",
"       \"Compatibility testing\", section on 'Antibody detection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This latter task, called pretransfusion antibody detection, involves the mixing of the patient's plasma with two or three reagent samples of red blood cells (RBCs) on which are represented all of the clinically important RBC antigens. If negative results are obtained, the patient may be safely transfused with ABO and Rh compatible blood, since the patient has no clinically significant RBC antibodies.",
"   </p>",
"   <p>",
"    On the other hand, if a positive test is found with one or more of the screening cells, further investigation is indicated to evaluate the identity of the antibody. This involves testing the patient's plasma against a panel of 10 or more phenotyped RBCs. This usually results in identification of the offending antibody. Compatible blood may then be selected which lacks the corresponding antigen(s). At times the patient's plasma reacts with all of the RBCs on the panel (panagglutination), resulting in incompatible crossmatches with all of the donor blood available, making antibody identification and selection of compatible blood complicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three major clinical situations that may lead to difficulty in providing crossmatch compatible blood:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alloantibodies due to previous transfusions or pregnancy",
"     </li>",
"     <li>",
"      Autoantibodies reacting with common RBC antigens in autoimmune hemolytic anemia (AIHA) and some forms of drug-induced immune hemolytic anemia",
"     </li>",
"     <li>",
"      ABO discrepancies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians need to be aware that laboratory testing to identify complex antibodies and provide compatible blood for transfusion is very time consuming (",
"    <a class=\"graphic graphic_algorithm graphicRef71949 \" href=\"UTD.htm?40/48/41728\">",
"     algorithm 1",
"    </a>",
"    ). Therefore, communication between the clinician and the transfusion medicine physician is crucial in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory personnel must let the clinician know the complexity of the laboratory testing, the estimated timeframe required to complete the testing, and what kind of patient history would be helpful to find possible causes of the incompatibility.",
"     </li>",
"     <li>",
"      The clinician must let the laboratory know the clinical urgency of transfusion, detailed pertinent history, and a treatment plan related to managing anemia and other concurrent medical problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best scenario occurs when the patient with an incompatible crossmatch is not in need of urgent transfusion. This allows for a complete immunohematologic evaluation and provision of compatible blood. However, for patients who are profoundly anemic and in urgent need of transfusion, a decision must be made based on an abbreviated laboratory evaluation. While this is being accomplished, the clinician can modify patient care (eg, oxygen supplementation, bed rest to decrease oxygen demand) while waiting for the availability of compatible blood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/3\">",
"     3",
"    </a>",
"    ]. A discussion of procedures that may be employed during this interim period can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link&amp;anchor=H20#H20\">",
"     \"The approach to the patient who refuses blood transfusion\", section on 'Alternative courses of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's medical history is very important and may provide clues to the cause of the incompatibility (",
"    <a class=\"graphic graphic_algorithm graphicRef70462 \" href=\"UTD.htm?39/44/40654\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of use of certain drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ) suggests that the patient may have drug-induced autoimmune hemolytic anemia (AIHA) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of a lymphoproliferative disorder (particularly chronic lymphocytic leukemia), autoimmune disease (particularly systemic lupus erythematosus), or immune deficiency disorder (particularly AIDS) suggests secondary AIHA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link\">",
"       \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of pregnancy or prior transfusion raises the possibility of multiple RBC alloantibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. If there is no history of transfusion in a man or a child, the likelihood that the patient has a significant RBC alloantibody is extremely low, if not impossible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"       \"Significance of minor red blood cell antibodies during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of difficulties in finding blood for family members suggests the presence of an alloantibody against a high frequency antigen (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Alloantibodies to high frequency antigens'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      A history of recent transfusion raises the possibility of a delayed hemolytic transfusion reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ALLOANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloantibodies against RBC antigens can be produced by patients who have been exposed to foreign RBCs by transfusion or pregnancy. Particular difficulty in providing compatible blood is encountered when such patients form either multiple alloantibodies or an antibody to a high frequency RBC antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Common alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever the antibody screening test is positive, the blood bank will perform studies to identify the specificity of the offending antibody or antibodies (",
"    <a class=\"graphic graphic_figure graphicRef53831 \" href=\"UTD.htm?9/34/9760\">",
"     figure 1",
"    </a>",
"    ). The most common alloantibodies detected are anti-E, anti-Le(a), anti-K, anti-D, and anti-Le(b) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/11\">",
"     11",
"    </a>",
"    ]. Only antibodies that are capable of causing a hemolytic transfusion reaction or hemolytic disease of the newborn are considered clinically significant. Fortunately not all alloantibodies are clinically important. The following is a list of the common alloantibodies and their clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies that are ALWAYS considered to be potentially clinically significant include: ABO (A, B), Rh (D, C, c, E, e), Duffy (Fya, Fyb), Kidd (Jka, Jkb), Kell (K, k), SsU (S, s, U), and Lutheran (Lub)",
"     </li>",
"     <li>",
"      Antibodies that are rarely or never considered to be clinically significant include: Lewis (Lea, Leb), MN, Lutheran (Lua), P1, Xga, Cartwright (Yta), Bg, York (Yka),",
"      <span class=\"nowrap\">",
"       Chido/Rodgers",
"      </span>",
"      <span class=\"nowrap\">",
"       (Cha/Rga),",
"      </span>",
"      Sda, and HTLA (high titer low avidity)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In four series, the most frequent clinically significant alloantibodies encountered included anti-E, anti-K, anti-c, anti-Jk(a), and anti-Fy(a) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/10,13-15\">",
"     10,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alloantibody persistence and evanescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of importance, the titer of some acquired alloantibodies decreases with time, often to the point of evanescence or complete disappearance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/16\">",
"     16",
"    </a>",
"    ]. This is a less common finding with antibodies directed against Rh antigens, but is frequent among those developing anti-Jk(a), consistent with the large relative number of delayed hemolytic transfusion reactions mediated by anti-Jk(a). As an example, in a long-term study of the transfusion records of 304 male veterans with one or more alloantibodies and at least one follow-up alloantibody screening test, anti-D and anti-C alloantibodies were persistent in 94 and 86 percent, whereas anti-Jk(a) alloantibodies were persistent in only 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multiple alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial alloimmunization, 20 to 25 percent of non-hematology-oncology patients and 22 to 33 percent of hematology-oncology patients may develop additional red cell alloantibodies after subsequent transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one 10-year retrospective study of 564 patients with malignant hematologic disease, of the 51 patients who developed alloantibodies, 34, 14, and 3 produced one, two, and three different alloantibodies, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 390 alloimmunized pregnant women who had delivered 455 infants, a combination of two to four different alloantibodies was detected in 27 percent of the women [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/19\">",
"       19",
"      </a>",
"      ]. Combinations of alloantibody specificities appeared to be more harmful to the",
"      <span class=\"nowrap\">",
"       fetus/infant",
"      </span>",
"      than single specificities, suggesting a potentially synergistic effect.",
"     </li>",
"     <li>",
"      In a review of transfusion records at a Veterans Affairs medical center, multiple alloimmunization occurred in 21.7 percent of alloimmunized patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/20\">",
"       20",
"      </a>",
"      ]. The most common alloantibody pairs were",
"      <span class=\"nowrap\">",
"       anti-K/-E,",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-D/-C,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       anti-E/-c.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar situation occurs in patients with sickle cell disease (SCD) who require multiple transfusions during their lifetime. Approximately 25 percent of adults and 10 percent of children with SCD have multiple alloantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/21\">",
"     21",
"    </a>",
"    ]. This situation arises due to genetic differences among different ethnic populations in terms of the frequency of RBC antigens (",
"    <a class=\"graphic graphic_table graphicRef78046 \" href=\"UTD.htm?24/51/25405\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with SCD generally are African Americans, while most blood donors are Caucasians, resulting in unusually excessive exposure to certain antigens. The most common antibodies encountered in SCD patients are anti-E (21 percent), -C (14 percent), -K (14 percent), -Fy(a) (7 percent), -Jk(b) (5 percent), -S (4 percent), and &ndash;D (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the management of sickle cell disease\", section on 'Alloimmunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once these patients produce multiple alloantibodies, it is very difficult to provide compatible blood for transfusion. In order to avoid this situation, many hospital blood banks will phenotype the SCD patient's RBCs and provide blood that is matched for ABO, Rh, and Kell antigens (partially phenotypically matched RBCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/22\">",
"     22",
"    </a>",
"    ]. Even though the transfused RBCs are not completely matched with the patient's phenotype, patients rarely become alloimmunized to any RBC antigen when using this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the mechanism of prevention of all alloantibody production by matching for only certain antigens is not well understood.",
"   </p>",
"   <p>",
"    In our own experience over the past 10 years after we began providing ABO, Rh, and Kell antigen matched blood for non-alloimmunized patients with SCD, we have not seen a single new alloantibody in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Alloantibodies to high frequency antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency antigens, such as U, Vel, k, Lu(b), and Yt(a) are present in more than 99.8 percent of the population. If a patient lacks a high frequency antigen, he or she can make an alloantibody against this antigen. Because these antigens are present on almost all donor RBCs, crossmatches will be positive with virtually all randomly selected units of blood. A family history of difficulty in finding compatible blood for transfusion is a valuable clue to this diagnosis.",
"   </p>",
"   <p>",
"    Identification of antibodies to high frequency antigens requires rare reagent RBCs lacking these antigens. Such reagent RBCs are not available at the average hospital blood bank; a reference laboratory must be consulted in order to identify these rare antibodies. In such cases, significant delays can be expected in securing safe, compatible units of blood for transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Delayed hemolytic transfusion reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a recently transfused patient is experiencing active red cell destruction and has a positive direct antiglobulin test (DAT, Coombs' test), the clinical and serologic findings may mimic those found in patients with autoimmune hemolytic anemia. If the antibody identification test demonstrates a specific alloantibody in the patient's plasma and the same alloantibody is also present in an eluate prepared from the patient's RBCs (",
"    <a class=\"graphic graphic_figure graphicRef53831 \" href=\"UTD.htm?9/34/9760\">",
"     figure 1",
"    </a>",
"    ), a diagnosis of delayed hemolytic transfusion reaction can be made and compatible blood can be provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H11#H11\">",
"     \"Immunologic blood transfusion reactions\", section on 'Delayed hemolytic reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link&amp;anchor=H4#H4\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\", section on 'Delayed hemolytic transfusion reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Identification of blood for transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of all of the above procedures is to arrive at the proper diagnosis, identify the offending antibody(s) and provide compatible blood for transfusion. Finding compatible blood for patients with multiple RBC alloantibodies or antibodies against high frequency antigens may be very time consuming and is dependent upon the availability of blood lacking the corresponding antigens to which the patient has formed antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Patients with multiple alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with multiple antibodies, the difficulty in finding compatible blood is based on the probability finding the antigen(s) in the donor population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/24\">",
"     24",
"    </a>",
"    ]. If a patient is Type O Rh negative with anti-K, anti-Jk(b), and anti-Fy(a), in order to find one compatible unit of RBCs, the calculated theoretical chance is 0.006, or one out of 167 units (",
"    <a class=\"graphic graphic_table graphicRef55655 \" href=\"UTD.htm?14/46/15084\">",
"     table 2",
"    </a>",
"    ). In these situations, the hospital must work with the community blood center in order to obtain sufficient units of compatible blood for the patient. The blood center may also wish to store frozen units of blood for future transfusion needs of the patient; these can be stored up to 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Alloantibody to a high frequency antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another difficult-to-transfuse patient is one with an antibody to a high frequency antigen found on the majority of RBCs in the general population. Among these rare antibodies, some are clinically significant and some are not. Some tests such as the monocyte monolayer assay (MMA) and the chemiluminescence test have been used in predicting the clinical significance of RBC alloantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MMA is a highly technical and time consuming test. Both tests are only available in reference laboratories. If the alloantibody is not clinically significant, multiple random units can be crossmatched with the patient's plasma. The most compatible units can be safely transfused. If the alloantibody is clinically significant, the following options are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rare donor file may be contacted for compatible blood, usually via the regional blood center. Identification and delivery of compatible blood may take several days.",
"     </li>",
"     <li>",
"      The patient's close family members, especially siblings, may be tested to determine if one or more of them also lack the same RBC antigen in question and may serve as blood donors.",
"     </li>",
"     <li>",
"      The patient may serve as his or her own source of fully compatible RBCs by virtue of autologous donations, when the need can be anticipated, such as prior to elective surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"       \"Preoperative autologous blood donation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AUTOANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of autoantibodies that may be responsible for causing incompatible crossmatches: warm reactive autoantibodies (usually IgG), cold reactive autoantibodies (usually IgM), and drug-induced autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Warm autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Warm autoimmune hemolytic anemia (WAIHA) is the most common type of AIHA. In one study, WAIHA represented 70.3 percent of the cases of AIHA that were encountered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/28\">",
"     28",
"    </a>",
"    ]. WAIHA can be idiopathic or secondary to the presence of an underlying disease, such as a lymphoproliferative, autoimmune, or immune deficiency disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In WAIHA the autoantibody reacts optimally with human RBCs at 37&ordm;C and usually is IgG, but rarely may be IgM or IgA. The direct antiglobulin test (DAT, Coombs' test) will be positive in patients with AIHA, but this is a nonspecific test that can be positive in as many as 10 percent of hospitalized patients who do not have hemolytic anemia associated with the presence of autoantibodies. The incidence of true AIHA is 1 in 80,000 in most published reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cold agglutinin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autoantibody in cold agglutinin disease (CAD) shows optimal reactivity at 4 to 30&ordm;C and usually is an IgM antibody. The DAT is positive, due to coating of the patient's RBCs with complement components. Patients with this disorder suffer episodic anemia upon exposure to cold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Drug-induced AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced AIHA shows similar findings in the laboratory as WAIHA, but the anemia recovers when the implicated drug is discontinued, and may recur if the same drug is readministered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/5\">",
"     5",
"    </a>",
"    ]. Examples of drugs that may be implicated include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     AIHA and concurrent alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest concern in transfusing patients with AIHA involves detection of concurrent alloantibodies in the patient's plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/30\">",
"     30",
"    </a>",
"    ]. The presence of a masking autoantibody makes alloantibody detection and identification more difficult. As an example of their prevalence in this setting, one study indicated that 31 percent of subjects with a warm autoantibody also had at least one alloantibody. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Presence of alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several techniques can be used to detect an underlying alloantibody [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. The most powerful test is the autoadsorption method (",
"    <a class=\"graphic graphic_figure graphicRef68773 \" href=\"UTD.htm?28/25/29072\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/6,7,9,31\">",
"     6,7,9,31",
"    </a>",
"    ]. The autoantibody coating the patient's RBCs is driven off the cells by an elution method. The patient's own eluted RBCs are then mixed with the patient's plasma. These cells will adsorb the autoantibodies from the plasma, but alloantibodies cannot be adsorbed since the patient does not have the corresponding antigen on his or her own RBCs. Mixing is continued multiple times until all of the autoantibody is removed from the plasma. If the patient has an alloantibody, it can now be detected and identified. There are, however, several drawbacks to this method:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It cannot be used in a recently transfused patient.",
"     </li>",
"     <li>",
"      The autoantibody may be difficult to adsorb, either because the antibody titer is too high or the patient's RBCs are too fragile for any manipulation.",
"     </li>",
"     <li>",
"      It is very time consuming.",
"     </li>",
"     <li>",
"      There is often a requirement for more blood samples from an already anemic patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When autoadsorption is not possible, an alternate method called allogeneic adsorption is available by using allogeneic RBCs of varying phenotypes to adsorb autoantibody from the patient's plasma, leaving behind the alloantibody, if present, for subsequent identification [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/6,7,31,34,35\">",
"     6,7,31,34,35",
"    </a>",
"    ]. Details of these methods are beyond the scope of this discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Identification of blood for transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The provision of blood for patients with cold-reacting antibodies may not present a major challenge as long as all testing and crossmatching is performed at 37&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ]. However, in warm AIHA the patient has autoantibodies which react at 37&ordm;C and are panagglutinins directed against a common RBC antigen present on the patient's and virtually all RBCs. Therefore, it is impossible to provide \"crossmatch compatible\" blood for these patients. Fortunately, these patients generally tolerate transfusion of such incompatible blood without suffering serious hemolytic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/8,10,36\">",
"     8,10,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the survival of these transfused RBCs is shortened, it is not significantly different from the survival of the patient's own RBCs. One report, for example, described 53 patients who received blood transfusions because of decompensated AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/8\">",
"     8",
"    </a>",
"    ]. No patient had a definite increase in hemolysis, even when the transfused RBCs were serologically incompatible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Presence of alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an effort to provide the greatest degree of compatibility, there are several approaches the laboratory can take:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crossmatch a number of units (10 to 20) and select the most compatible blood components (ie, among all the crossmatched units, select the units with the weakest positive reactions). This approach is especially useful in the situation where the patient is urgently in need of blood transfusion and no time is available to wait for a complete laboratory workup.",
"     </li>",
"     <li>",
"      Phenotype or genotype the patient's RBCs. If the patient's extended RBC phenotype is known, transfusion can be accomplished safely by providing phenotypically matched RBCs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In most cases this information is not available to the blood bank. If phenotyping is to be pursued, this should be done prior to the initial transfusion. Since the patient's RBCs are coated in vivo with autoantibody, techniques such as the EDTA-glycin acid method or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      method need to be employed to dissociate autoantibody from the patient's RBCs before phenotyping. Genotyping tests have become available in reference laboratories that can be performed on patients who have had recent transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/39\">",
"       39",
"      </a>",
"      ]. However, these techniques are not available in most hospital blood banks.",
"     </li>",
"     <li>",
"      Perform autoadsorption to remove autoantibodies from the patient's plasma and then use the adsorbed plasma to crossmatch donor RBC units. This is the best method for finding a compatible unit of blood (",
"      <a class=\"graphic graphic_figure graphicRef68773 \" href=\"UTD.htm?28/25/29072\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'AIHA and concurrent alloantibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     In vivo crossmatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo crossmatch procedures have been reported in the literature as a method for predicting the compatibility of individual units of blood for transfusion. Two techniques for performing an in vivo crossmatch have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One method involves the intravenous injection of 1.0 mL of 51Cr-labeled RBCs from the selected unit to be transfused. Radioactivity in the recipient's blood is measured at 10 and 60 minutes following the injection [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/40\">",
"       40",
"      </a>",
"      ]. If &gt;70 percent of the RBCs survive for the first 60 minutes, the unit of blood is considered to be compatible. This test is not available in most hospitals.",
"     </li>",
"     <li>",
"      A second method involves the infusion of 20 to 30 mL of RBCs from the selected unit of blood. After waiting for approximately 30 minutes, during which time the patient is observed for signs and symptoms of a hemolytic transfusion reaction, a blood sample is obtained and examined for the presence of hemoglobinemia, signifying rapid intravascular hemolysis of the infused cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, our own experience suggests that in vivo crossmatch techniques are not practical in the hospital setting and can yield misleading results. We have encountered several instances where such testing suggested that a unit of blood was compatible, but following transfusion of the entire unit the patient suffered a hemolytic transfusion reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ABO DISCREPANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even though ABO typing is a simple test with 100 percent accuracy being required, there are occasional difficulties in determining the patient's true ABO type. Such ABO discrepancies may cause positive crossmatches with some or all units of donor blood. Most issues can be resolved after careful laboratory investigation. If the patient is in need of urgent transfusion, type O blood can be safely transfused.",
"   </p>",
"   <p>",
"    The following are the common causes of ABO discrepancies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type A subgroups &mdash; Among all type A patients, 80 percent are type A1 and 20 percent are either type A2 or another subtype of A. Patients who are a subgroup of A can have anti-A1 antibodies that will result in positive crossmatches with A1 donor units. Type O blood should be provided to these patients. DNA-based red cell genotyping may be of value in such cases by providing optimally matched donations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acquired B phenotype &mdash; When group A patients are infected with certain Gram negative bacteria, bacterial enzymes can remove an N-acetyl group from N-acetylgalactosamine on the red cell surface, resulting in galactosamine that is similar to the group B antigen's terminal galactose. ABO typing will show a weak B antigen on the patient's RBCs with strong anti-B in the plasma (normally type B patients should not have anti-B in their plasma). If the patient's plasma is crossmatched with type B donor units, the results will be incompatible. The patient's RBCs can be correctly typed by acidifying the anti-B typing reagent, which will not recognize this \"acquired B antigen\" and resolve the problem. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H9#H9\">",
"       \"A primer of red blood cell antigens and antibodies\", section on 'Acquired B antigen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have received ABO mismatched bone marrow or stem cell transplants will have a different ABO type than is indicated in their historical medical records. This causes confusion in ABO typing and can result in positive crossmatches. For example, type O patients who receive stem cell transplants from type A donors will have type A RBCs after engraftment, but may transiently continue to have anti-A in their plasma produced by their residual lymphocytes (normal type A patient should not have anti-A in the plasma). If the patient's plasma is crossmatched against a type A donor unit, a positive result will be obtained. In this case, type O blood should be provided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the time required to perform the above testing, the severity of the patient's condition determines clinical management during the laboratory evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef74608 \" href=\"UTD.htm?34/18/35118\">",
"     algorithm 3",
"    </a>",
"    ). The patient's ability to withstand severe anemia while awaiting transfusion can be maximized by enforced bed rest to decrease oxygen demand and the administration of supplemental oxygen to optimize dissolved oxygen in the plasma. In critical situations other options may be available. These are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link&amp;anchor=H20#H20\">",
"     \"The approach to the patient who refuses blood transfusion\", section on 'Alternative courses of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed history regarding prior transfusions and pregnancies is very important. If the patient has never been exposed to any foreign RBCs in the past, it is highly unlikely that an alloantibody could be present. With this vital information, transfusion can proceed more quickly with ABO matched blood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. The remainder of the work-up can be completed after issue of the unit of blood.",
"   </p>",
"   <p>",
"    This is an ideal opportunity for joint decision making by the clinician and transfusion medicine physician [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <strong>",
"     NO PATIENT WITH AIHA SHOULD BE DENIED A LIFESAVING TRANSFUSION BECAUSE OF DIFFICULTIES IN FINDING COMPATIBLE BLOOD FOR TRANSFUSION",
"    </strong>",
"    ; such patients will tolerate serologically incompatible blood without significant complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27480/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H15\">",
"     'Autoantibodies'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    We urge that the best practice for attempting to transfuse these patients safely is to infuse blood slowly while carefully observing the patient for signs and symptoms of an acute hemolytic transfusion reaction (eg, fever, chills, respiratory distress, or pain in the chest or back). In the event of such signs or symptoms, the transfusion should be discontinued immediately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\", section on 'Immune mediated hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25142625\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major clinical situations that may lead to difficulty in providing crossmatch compatible blood include the presence of alloantibodies, autoantibodies reacting with common RBC antigens in immune hemolytic anemia, and ABO discrepancies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Alloantibodies",
"      </strong>",
"      can be produced by patients who have been exposed to foreign RBCs by transfusion or pregnancy. Particular difficulty is encountered when such patients form either multiple alloantibodies or an antibody to a high frequency RBC antigen. Finding compatible blood for such patients may be very time consuming and is dependent upon the availability of blood lacking the corresponding antigens to which the patient has formed antibodies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Alloantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Autoantibodies",
"      </strong>",
"      can be produced in patients with warm reactive autoantibodies (usually IgG), cold reactive autoantibodies (usually IgM), and drug-induced autoantibodies. The greatest concern in transfusing patients with such autoantibodies involves detection of concurrent alloantibodies in the patient's plasma. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       ABO discrepancies",
"      </strong>",
"      can occur in patients with type A subgroups, in group A patients infected with Gram negative bacteria, and following ABO mismatched hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'ABO discrepancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the time required to perform the above testing, the severity of the patient's condition determines clinical management during the laboratory evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef74608 \" href=\"UTD.htm?34/18/35118\">",
"     algorithm 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Clinical management'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/1\">",
"      Petz LD. \"Least incompatible\" units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? A commentary for clinicians and transfusion medicine professionals. Transfusion 2003; 43:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/2\">",
"      Chiaroni J, Gouvitsos J, Dettori I, Ferrera V. How we evaluate panagglutinating sera. Transfusion 2009; 49:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/3\">",
"      Petz LD. A physician's guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 2004; 124:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/4\">",
"      Kleinman S, Nelson R, Smith L, Goldfinger D. Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide. N Engl J Med 1984; 311:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/5\">",
"      Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005; 42:137.",
"     </a>",
"    </li>",
"    <li>",
"     Petz L. Blood transfusion in acquired hemolytic anemias. In: Clinical Practice of Transfusion Medicine, Petz L (Ed), Churchill Livingstone, New York 1996. p.469.",
"    </li>",
"    <li>",
"     Gilliland B. Autoimmune hemolytic anemia. In: Principles of Transfusion Medicine, Rossi E (Ed), Williams Wilkins, Baltimore 1996. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/8\">",
"      Salama A, Bergh&ouml;fer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/9\">",
"      Garratty G. Mechanisms of immune red cell destruction, and red cell compatibility testing. Hum Pathol 1983; 14:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/10\">",
"      Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol 1988; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/11\">",
"      Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48:2069.",
"     </a>",
"    </li>",
"    <li>",
"     Harmening DM. Modern blood banking and transfusion practices, 5th ed, F.A. Davis Company, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/13\">",
"      Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999; 39:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/14\">",
"      Pineda AA, Vamvakas EC, Gorden LD, et al. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion 1999; 39:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/15\">",
"      Schonewille H, Brand A. Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens? Transfusion 2008; 48:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/16\">",
"      Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009; 114:4279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/17\">",
"      Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009; 49:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/18\">",
"      Schonewille H, de Vries RR, Brand A. Alloimmune response after additional red blood cell antigen challenge in immunized hematooncology patients. Transfusion 2009; 49:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/19\">",
"      Nordvall M, Dziegiel M, Hegaard HK, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009; 49:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/20\">",
"      Tormey CA, Stack G. The characterization and classification of concurrent blood group antibodies. Transfusion 2009; 49:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/21\">",
"      Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 1997; 37:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/22\">",
"      Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/23\">",
"      Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129:190.",
"     </a>",
"    </li>",
"    <li>",
"     Menitove J. The Hardy-Weinberg principle: Selection of compatible blood based on mathematic principles. In: Numbers for Blood Bankers, Fridey J (Ed), American Association of Blood Banks, Bathesda 1995. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/25\">",
"      Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004; 44:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/26\">",
"      Noble AL, Poole GD, Anderson N, et al. Predicting the severity of haemolytic disease of the newborn: an assessment of the clinical usefulness of the chemiluminescence test. Br J Haematol 1995; 90:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/27\">",
"      Mazzara R, Lozano M, Salmer&oacute;n JM, et al. Transfusion of incompatible RBCs to a patient with alloanti-Kp(b). Transfusion 2001; 41:611.",
"     </a>",
"    </li>",
"    <li>",
"     Petz L, Garratty G. Immune hemolytic anemias, Churchill Livingstone, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/29\">",
"      Sokol RJ, Booker DJ, Stamps R. The pathology of autoimmune haemolytic anaemia. J Clin Pathol 1992; 45:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/30\">",
"      Blackall DP. How do I approach patients with warm-reactive autoantibodies? Transfusion 2011; 51:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/31\">",
"      Petz LD. Autoimmune hemolytic anemia. Hum Pathol 1983; 14:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/32\">",
"      &Oslash;yen R, Angeles ML. A simple screening method to evaluate the presence of alloantibodies with concomitant warm autoantibodies. Immunohematology 1995; 11:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/33\">",
"      Branch DR, Petz LD. A new reagent (ZZAP) having multiple applications in immunohematology. Am J Clin Pathol 1982; 78:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/34\">",
"      Leger RM, Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion 1999; 39:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/35\">",
"      Cid J, Ort&iacute;n X, Pinacho A, et al. Use of polyethylene glycol for performing autologous adsorptions. Transfusion 2005; 45:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/36\">",
"      Garratty G, Petz LD. Approaches to selecting blood for transfusion to patients with autoimmune hemolytic anemia. Transfusion 2002; 42:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/37\">",
"      Svensson AM, Bushor S, Fung MK. Case report: exacerbation of hemolytic anemia requiring multiple incompatible RBC transfusions. Immunohematology 2004; 20:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/38\">",
"      Shirey RS, Boyd JS, Parwani AV, et al. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002; 42:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/39\">",
"      Reid ME. Applications of DNA-based assays in blood group antigen and antibody identification. Transfusion 2003; 43:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/40\">",
"      Silvergleid AJ, Wells RF, Hafleigh EB, et al. Compatibility test using 51chromium-labeled red blood cells in crossmatch positive patients. Transfusion 1978; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/41\">",
"      Mayer K, Bettigole RE, Harris JP, D'Amaro J. Test in vivo to determine donor blood compatibility. Transfusion 1968; 8:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27480/abstract/42\">",
"      Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood 2009; 114:248.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7954 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27480=[""].join("\n");
var outline_f26_53_27480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25142625\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CROSSMATCHING OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALLOANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Common alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alloantibody persistence and evanescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multiple alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Alloantibodies to high frequency antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Delayed hemolytic transfusion reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Identification of blood for transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Patients with multiple alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Alloantibody to a high frequency antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AUTOANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Warm autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Drug-induced AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AIHA and concurrent alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Identification of blood for transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      In vivo crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ABO DISCREPANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25142625\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7954|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/48/41728\" title=\"algorithm 1\">",
"      Eval incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/44/40654\" title=\"algorithm 2\">",
"      History incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/18/35118\" title=\"algorithm 3\">",
"      Rx incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7954|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/34/9760\" title=\"figure 1\">",
"      Antibody elution technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/25/29072\" title=\"figure 2\">",
"      Autoabsorption method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7954|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/51/25405\" title=\"table 1\">",
"      RBC antigens ethnic popul",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/46/15084\" title=\"table 2\">",
"      Calculate compatible blood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_53_27481="Pathology of bladder neoplasms";
var content_f26_53_27481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology of bladder neoplasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Cristina Magi-Galluzzi, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Ming Zhou, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27481/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/53/27481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is the most common malignancy involving the urinary system. Urothelial (transitional cell) carcinoma is the predominant histologic type in the United States and Europe, where it accounts for 90 percent of all bladder cancers. In other areas of the world, non-urothelial carcinomas are more frequent. Much less commonly, urothelial cancers can arise in the renal pelvis, ureter, or urethra. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathology of bladder neoplasms will be reviewed here. Clinical aspects of these different tumor types are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"     \"Nonurothelial bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systems have been used to grade and classify bladder neoplasms. The system proposed by the World Health Organization (WHO) in 1972 distinguished papillomas from grades I, II, and III papillary transitional cell carcinomas (TCCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1998, the WHO and the International Society of Urologic Pathologists (ISUP) published a consensus classification system for urothelial (transitional cell) neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical significance of this schema was validated by subsequent studies, and in 2004, it was accepted as the standard classification schema [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to this system, urothelial cancer (UC) is classified as low-grade and high-grade based upon the degree of nuclear anaplasia and architectural abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef51333 \" href=\"UTD.htm?19/56/20356\">",
"     figure 1",
"    </a>",
"    ). With rare exceptions (eg, nested or tubular variants), invasive UC is high grade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bladder anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wall of the bladder consists of four layers (",
"    <a class=\"graphic graphic_picture graphicRef55649 \" href=\"UTD.htm?27/19/27959\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urothelium &mdash; The urothelium is the innermost epithelial lining of the bladder. The urothelium is the site of origin for urothelial carcinomas.",
"     </li>",
"     <li>",
"      Lamina propria &mdash; The lamina propria is separated from the urothelium by a thin basement membrane that is composed of abundant connective tissue containing vascular and neuronal structures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. Wispy fascicles of smooth muscle can be found within the superficial lamina propria, either isolated or forming a complete or incomplete muscularis mucosae [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscularis propria &mdash; The muscularis propria (detrusor muscle) surrounds the lamina propria and consists of thick, irregularly arranged muscle bundles. In small biopsies, fascicles of muscle in the lamina propria may be confused with the larger smooth muscle bundles of the muscularis propria, potentially resulting in an error in tumor staging. Adipose tissue also can be present within the lamina propria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      muscularis propria [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/2\">",
"       2",
"      </a>",
"      ]. The presence of invasive tumor in fat thus is not always indicative of extravesical extension.",
"     </li>",
"     <li>",
"      Adventitia or serosa &mdash; The muscularis propria is separated from the surrounding tissues by a serosal layer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathologic tumor staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important element in the pathologic staging of UC is the extent of invasion into deeper layers of the bladder and surrounding tissues (",
"    <a class=\"graphic graphic_figure graphicRef51333 \" href=\"UTD.htm?19/56/20356\">",
"     figure 1",
"    </a>",
"    ). The depth of invasion is incorporated into the American Joint Committee on",
"    <span class=\"nowrap\">",
"     Cancer/Tumor",
"    </span>",
"    Metastasis Nodes Classification schema",
"    <span class=\"nowrap\">",
"     (AJCC/TNM)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ). This information has major implications for both prognosis and treatment.",
"   </p>",
"   <p>",
"    Most pT1 tumors are low- or high-grade papillary UCs, while the more deeply invasive pT2 to pT4 UCs are nonpapillary and high-grade. Several studies showed that pT1 tumors have a less favorable prognosis than pTa neoplasms. However, pTa and pT1 neoplasms are grouped together because both pTa and pT1 lesions are managed conservatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link\">",
"     \"Treatment of non-muscle-invasive bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lamina propria invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of lamina propria invasion by UC can be extremely difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/9\">",
"     9",
"    </a>",
"    ]. Biopsy specimens are often poorly oriented, fragmented,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cauterized. In pT1 disease, foci of invasion are characterized by urothelial nests, clusters, or single cells within the papillary cores",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lamina propria (",
"    <a class=\"graphic graphic_picture graphicRef73869 \" href=\"UTD.htm?41/23/42357\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The invasive nests can induce a desmoplastic stromal response that mimics a malignant spindle cell component, a feature known as pseudosarcomatous stromal reaction (",
"    <a class=\"graphic graphic_picture graphicRef73869 \" href=\"UTD.htm?41/23/42357\">",
"     picture 2",
"    </a>",
"    ). In addition, foci of invasive tumor may be associated with retraction artifact, mimicking vascular invasion (",
"    <a class=\"graphic graphic_picture graphicRef73869 \" href=\"UTD.htm?41/23/42357\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the WHO classification does not substage pT1 tumors according to the depth of lamina propria invasion, some studies have demonstrated prognostic differences in tumors with invasion above and below the muscularis mucosae. Therefore, pathologists should provide the extent of lamina propria invasion if such assessment is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Muscularis propria invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In more advanced stages, UC infiltrates the muscularis propria (pT2) (",
"    <a class=\"graphic graphic_picture graphicRef74142 \" href=\"UTD.htm?20/37/21076\">",
"     picture 3",
"    </a>",
"    ) or adipose tissue and surrounding organs (pT3 and pT4) (",
"    <a class=\"graphic graphic_picture graphicRef76177 \" href=\"UTD.htm?41/19/42296\">",
"     picture 4",
"    </a>",
"    ). Muscularis propria invasion is diagnosed when UC infiltrates between thick distinct fascicles of muscle bundles (",
"    <a class=\"graphic graphic_picture graphicRef74142 \" href=\"UTD.htm?20/37/21076\">",
"     picture 3",
"    </a>",
"    ). Muscle invasion by UC may or may not elicit a desmoplastic stromal response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncertainty about the depth of invasion should be explicitly stated in the pathology report [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/4\">",
"     4",
"    </a>",
"    ]. Even in cases of noninvasive disease, the pathologist should note whether muscularis propria was present in the biopsy specimen to provide information regarding the adequacy of resection.",
"   </p>",
"   <p>",
"    Adipose tissue is often present between detrusor muscle bundles. Thus the presence of tumor in fat in a biopsy does not necessarily equate with involvement of perivesical fat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Vascular Invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the presence of vascular invasion is difficult (",
"    <a class=\"graphic graphic_picture graphicRef55403 \" href=\"UTD.htm?32/21/33111\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. UCs are commonly associated with stromal retraction artifact that mimics vascular invasion. Caution is warranted and rigid criteria should be applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONINVASIVE UROTHELIAL NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal urothelial mucosa is flat and consists of a layer of three to seven cells, although the thickness depends upon the extent of bladder distension at the time of biopsy. Normal urothelial cells are approximately two to three times larger than stromal lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef80375 \" href=\"UTD.htm?2/12/2247\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Noninvasive urothelial lesions are divided into flat and papillary subgroups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Flat lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flat noninvasive lesions of the urothelium include dysplasia and carcinoma in situ (CIS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplasia (low-grade intraurothelial neoplasia) is diagnosed when atypical dysplastic changes in urothelial cells do not meet the criteria for CIS. Areas of dysplasia are commonly associated with higher grade bladder neoplasia, and the incidence of dysplasia approaches 100 percent in patients with invasive UC. Primary (de novo) dysplasia without CIS or invasive UC is seen predominantly in middle-aged men, who present with symptoms of bladder irritation with or without hematuria.",
"   </p>",
"   <p>",
"    Dysplastic lesions show variable loss of cell polarity with nuclear crowding and cytologic atypia (",
"    <a class=\"graphic graphic_picture graphicRef60337 graphicRef69993 graphicRef81871 \" href=\"UTD.htm?17/35/17978\">",
"     picture 7A-C",
"    </a>",
"    ). The cells may have slightly enlarged nuclei, inconspicuous nucleoli, and rare mitoses (",
"    <a class=\"graphic graphic_picture graphicRef60337 \" href=\"UTD.htm?6/29/6610\">",
"     picture 7A",
"    </a>",
"    ). The degree of atypia is comparable to that seen within noninvasive, low-grade papillary UC. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'LGPUC'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The thickness of the urothelium in dysplastic lesions is usually normal (",
"    <a class=\"graphic graphic_picture graphicRef60337 graphicRef69993 graphicRef81871 \" href=\"UTD.htm?17/35/17978\">",
"     picture 7A-C",
"    </a>",
"    ), although it may be increased (",
"    <a class=\"graphic graphic_picture graphicRef69993 \" href=\"UTD.htm?39/25/40340\">",
"     picture 7B",
"    </a>",
"    ) or decreased. Urothelial dysplasia may involve von Brunn nests. Comparison with normal-appearing urothelium may help assess nucleomegaly and loss of polarity. The presence of pleomorphism, prominent nucleoli, and increased numbers of mitoses suggest a diagnosis of CIS.",
"   </p>",
"   <p>",
"    The finding of dysplasia in patients with noninvasive papillary neoplasms indicates urothelial instability and is a marker for potential progression or recurrence. De novo dysplasia progresses to CIS or invasive carcinoma in between 5 and 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Papillary lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Carcinoma in situ",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIS is a flat lesion in which the surface epithelium contains cells that are cytologically malignant. CIS is synonymous with high-grade intraurothelial neoplasia.",
"   </p>",
"   <p>",
"    De novo (primary) CIS accounts for less than 1 to 3 percent of urothelial neoplasms. Areas of CIS are also identified in 45 to 65 percent of patients with invasive UCs. Patients with primary CIS are typically in their 40s or 50s, and may be asymptomatic or have dysuria, frequency, urgency, or hematuria. Multifocal involvement of the urinary tract with CIS is common and may be synchronous or metachronous (",
"    <a class=\"graphic graphic_picture graphicRef65140 \" href=\"UTD.htm?24/54/25443\">",
"     picture 8",
"    </a>",
"    ). Endoscopically, CIS is characterized by irregularly hyperemic mucosa (",
"    <a class=\"graphic graphic_picture graphicRef76927 \" href=\"UTD.htm?5/20/5444\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Severe cytologic atypia is required to diagnose CIS (",
"    <a class=\"graphic graphic_picture graphicRef58125 graphicRef69860 graphicRef75477 graphicRef55750 \" href=\"UTD.htm?39/1/39962\">",
"     picture 10A-D",
"    </a>",
"    ). The degree of nuclear anaplasia is identical to high-grade papillary UC, although a spectrum of severity may exist. There may be complete loss of polarity, marked crowding, and pleomorphism (",
"    <a class=\"graphic graphic_picture graphicRef69860 graphicRef75477 graphicRef55750 \" href=\"UTD.htm?28/37/29274\">",
"     picture 10B-D",
"    </a>",
"    ). The nuclei are enlarged, frequently hyperchromatic, and have coarse or condensed chromatin. Most nuclei in CIS are approximately four to five times the size of adjacent stromal lymphocytes. Large nucleoli may be present. Mitoses are common, may be atypical, and can extend into the upper cell layers.",
"   </p>",
"   <p>",
"    The neoplastic changes may or may not involve the entire thickness of the epithelial layer, and umbrella cells may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The urothelium may be denuded, diminished in thickness, of normal thickness, or even hyperplastic (",
"    <a class=\"graphic graphic_picture graphicRef58125 graphicRef69860 \" href=\"UTD.htm?28/41/29335\">",
"     picture 10A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Different cytologic and architectural patterns are recognized in CIS. These include lesions characterized by pleomorphic large cells, nonpleomorphic large cells, small cells, clinging, and pagetoid features. Cystitis cystica and von Brunn nests may be completely or partially replaced by cytologically malignant cells (",
"    <a class=\"graphic graphic_picture graphicRef75477 graphicRef55750 \" href=\"UTD.htm?0/11/185\">",
"     picture 10C-D",
"    </a>",
"    ). Loss of intracellular cohesion may result in a denuded surface (denuding cystitis) (",
"    <a class=\"graphic graphic_picture graphicRef67528 graphicRef82071 \" href=\"UTD.htm?32/3/32823\">",
"     picture 11A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data suggest that de novo CIS is less likely to progress to invasive UC than secondary CIS. Patients with CIS and concomitant invasive tumors have a higher mortality than patients with CIS and concomitant non-invasive tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Papillary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive papillary lesions of the bladder can be benign (urothelial papilloma, inverted papilloma), have malignant potential (papillary urothelial neoplasm of low malignant potential [PUNLMP]), or contain noninvasive low-grade papillary UC (LGPUC) or high-grade papillary UC (HGPUC). PUNLMP, LGPUC, and HGPUC typically present with hematuria and are more common in men, with a mean age at diagnosis in the 60s.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Urothelial papilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial papillomas are benign exophytic lesions characterized by simple nonbranching papillary fronds lined by normal-appearing urothelium lacking atypia. Urothelial papillomas account for 1 to 4 percent of bladder tumors; the male to female ratio is 1.9:1. Papillomas tend to occur in young patients and can be seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/19\">",
"     19",
"    </a>",
"    ]. The typical presenting symptom is hematuria.",
"   </p>",
"   <p>",
"    Most urothelial papillomas are located on the posterior or lateral walls of the bladder close to the ureteral orifices or in the urethra. The lesions are usually relatively small and single, although multifocal tumors can be present. The cystoscopic appearance is identical to other low-grade papillary urothelial neoplasms.",
"   </p>",
"   <p>",
"    Most papillomas have slender fibrovascular stalks (",
"    <a class=\"graphic graphic_picture graphicRef58742 \" href=\"UTD.htm?29/42/30377\">",
"     picture 12",
"    </a>",
"    ). Superficial umbrella cells are often prominent. Eosinophilic cytoplasm and prominent vacuolization are common findings. Urothelial atypia, other than that in umbrella cells, excludes the diagnosis of papilloma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/20\">",
"     20",
"    </a>",
"    ]. Mitoses are rare or absent.",
"   </p>",
"   <p>",
"    The clinical course is typically favorable, although urothelial papillomas rarely can recur and progress to higher-grade disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Inverted papilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inverted papillomas are benign tumors that originate from the overlying mucosa and grow into the stroma.",
"   </p>",
"   <p>",
"    Inverted papillomas comprise less than 1 percent of urothelial neoplasms and are typically diagnosed in men in their 50s and 60s [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/22\">",
"     22",
"    </a>",
"    ]. Hematuria or irritative symptoms are typical, although occasionally these tumors produce symptoms of obstruction. Most inverted papillomas are solitary and can vary in size up to 8 cm. Approximately 70 percent occur in the bladder, typically in the trigone. Inverted papillomas can also occur in the ureter, renal pelvis, and urethra. Cystoscopically, these are sessile, pedunculated, or rarely polypoid lesions with a smooth surface.",
"   </p>",
"   <p>",
"    Inverted papillomas are characterized by anastomosing islands and cords of normal urothelial cells (",
"    <a class=\"graphic graphic_picture graphicRef58322 \" href=\"UTD.htm?9/23/9590\">",
"     picture 13",
"    </a>",
"    ). The base of the lesion is well circumscribed. Urothelial cells may invaginate extensively into the lamina propria but not into the muscular bladder wall. In contrast to other papillary urothelial neoplasms, the peripheral portion of the cords demonstrates palisading basal cells (",
"    <a class=\"graphic graphic_picture graphicRef58322 \" href=\"UTD.htm?9/23/9590\">",
"     picture 13",
"    </a>",
"    ). The stromal component is minimal and lacks inflammation. Foci of nonkeratinizing squamous metaplasia are often present. Cytologic atypia is minimal to absent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Mitotic figures are rare and only seen at the periphery of the trabeculae.",
"   </p>",
"   <p>",
"    If these criteria are strictly applied in establishing the diagnosis, inverted papillomas are benign and only infrequently recur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     PUNLMP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary urothelial neoplasm of low malignant potential (PUNLMP) resembles urothelial papilloma, but is distinguished from the latter by thickening of the urothelium. PUNLMP occurs predominantly in the lateral and posterior walls of the bladder, close to the ureteral orifices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The papillae of PUNLMP are discrete, slender, and lined by a thickened multilayered urothelium with minimal to absent cytologic atypia (",
"    <a class=\"graphic graphic_picture graphicRef71290 \" href=\"UTD.htm?22/23/22900\">",
"     picture 14",
"    </a>",
"    ). The cell density is increased compared to normal. The polarity and the umbrella cell layer are preserved (",
"    <a class=\"graphic graphic_picture graphicRef71290 \" href=\"UTD.htm?22/23/22900\">",
"     picture 14",
"    </a>",
"    ). Rare mitoses may be present but are confined to the basal layers. In contrast to noninvasive LGPUC, PUNLMP is characterized by a proliferation of monotonous bland-appearing cells, lacking enlarged hyperchromatic nuclei.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     LGPUC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive low-grade papillary urothelial carcinoma (LGPUC) is characterized by an orderly overall appearance of the urothelium lining papillary fronds, but with easily recognizable variation in architectural and cytologic atypia. LGPUC predominantly involves the posterior or lateral wall of the bladder. In the majority of the cases the tumor is single, but two or more lesions can be present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LGPUC is characterized by slender, frequently branching, papillary fronds with minimal fusion (",
"    <a class=\"graphic graphic_picture graphicRef76012 \" href=\"UTD.htm?32/23/33139\">",
"     picture 15",
"    </a>",
"    ). The nuclei are uniformly enlarged with mild differences in shape, contour, and chromatin distribution (",
"    <a class=\"graphic graphic_picture graphicRef76012 \" href=\"UTD.htm?32/23/33139\">",
"     picture 15",
"    </a>",
"    ). Inconspicuous nucleoli may be present. Mitoses are infrequent and may occur at any level but usually are limited to the lower half. The finding of scattered hyperchromatic nuclei and more than rare mitotic figures best distinguishes LGPUC from PUNLMP.",
"   </p>",
"   <p>",
"    If a tumor contains a high-grade component of more than 5 percent, the lesion should be classified as HGPUC. In the rare cases with a high-grade component comprising less than 5 percent, the lesion is diagnosed as LGPUC with a comment indicating the presence of focal high-grade tumor, the significance of which is unknown. Progression to invasion is rare, although recurrence is common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to PUNLMPs, LGPUCs have a higher rate of recurrence (48 to 77 versus 25 to 47 percent) and progression (3 to 11 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     HGPUC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive high-grade papillary urothelial carcinoma (HGPUC) is characterized by a disorderly appearance of urothelium lining papillary fronds resulting from marked architectural and cytologic abnormalities. The endoscopic appearance varies from papillary to",
"    <span class=\"nowrap\">",
"     nodular/solid",
"    </span>",
"    sessile lesion. A single or multiple lesions may be present.",
"   </p>",
"   <p>",
"    The architectural disorder and cytologic atypia characteristic of HGPUC are easily recognizable at low magnification. The papillae are frequently fused and branching (",
"    <a class=\"graphic graphic_picture graphicRef53378 \" href=\"UTD.htm?18/28/18885\">",
"     picture 16",
"    </a>",
"    ). The thickness of the urothelium lining the papillae may vary considerably. The cells typically are not cohesive. The spectrum of cytologic pleomorphism ranges from moderate to marked (",
"    <a class=\"graphic graphic_picture graphicRef53378 \" href=\"UTD.htm?18/28/18885\">",
"     picture 16",
"    </a>",
"    ). Marked variation in nuclear polarity, size, shape, and chromatin pattern, in contrast to LGPUC, and nucleoli may be prominent. Mitotic figures frequently are seen at all levels of the urothelium (",
"    <a class=\"graphic graphic_picture graphicRef53378 \" href=\"UTD.htm?18/28/18885\">",
"     picture 16",
"    </a>",
"    ). Invasion into the lamina propria, both within the papillary cores and at the base of the lesions, is common and should be sought [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HGPUC has a high risk of progression; it is often associated with invasive disease at the time of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INVASIVE UROTHELIAL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive UC, also referred to as transitional cell carcinoma, is characterized by invasion beyond the basement membrane (",
"    <a class=\"graphic graphic_picture graphicRef82678 \" href=\"UTD.htm?2/49/2835\">",
"     picture 17",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Histologic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial carcinoma has a propensity for multidirectional differentiation. The term \"variant\" is used to describe a distinctively different histomorphologic phenotype of a certain type of neoplasm. Recently, the spectrum of microscopic forms of UC has been expanded to include several unusual histologic variants. Awareness of these unusual patterns may be critical to avoid diagnostic misinterpretations.",
"   </p>",
"   <p>",
"    UCs often exhibit elements of squamous or glandular differentiation, which is more common in high-grade and high-stage lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The WHO classification recognizes several different histologic subtypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Squamous differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous differentiation is present in about 20 percent of UCs of the bladder and 44 percent of tumors of the renal pelvis (",
"    <a class=\"graphic graphic_picture graphicRef69814 \" href=\"UTD.htm?28/21/29017\">",
"     picture 18",
"    </a>",
"    ). True squamous differentiation requires evidence of keratinization, intercellular bridges, or both and should be obvious on routine hematoxylin and eosin (H&amp;E) staining. The presence of squamous differentiation does not seem to affect prognosis, although these tumors may be less likely to respond to chemotherapy and radiation treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3,30\">",
"     3,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Glandular differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glandular differentiation is present in about 6 percent of cases and is defined as the presence of true glandular spaces within the urothelial component of the tumor (",
"    <a class=\"graphic graphic_picture graphicRef78834 \" href=\"UTD.htm?19/22/19814\">",
"     picture 19",
"    </a>",
"    ). It may consist of tubular or enteric glands with mucin secretions. Intracytoplasmic mucin does not indicate glandular differentiation. The presence of glandular differentiation and mucin positivity in UCs does not affect the prognosis for any given stage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3,30\">",
"     3,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nested variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nested variant of UC is an uncommon aggressive neoplasm with a deceptively benign appearance that closely resembles von Brunn nests infiltrating the lamina propria. Useful features in recognizing this lesion as malignant include the presence of muscle invasion, irregularly invading crowded nests, and the tendency for increasing atypia in the deeper portion of the lesion (",
"    <a class=\"graphic graphic_picture graphicRef62076 \" href=\"UTD.htm?2/11/2231\">",
"     picture 20",
"    </a>",
"    ). There is a marked male predominance. Despite treatment, 70 percent of cases are dead within three to four years of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Microcystic variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;UCs occasionally show a striking microcystic pattern (",
"    <a class=\"graphic graphic_picture graphicRef56532 \" href=\"UTD.htm?22/60/23494\">",
"     picture 21",
"    </a>",
"    ). Cysts can range from microscopic up to 1 to 2 mm in diameter and may contain necrotic material or pink pale secretions (",
"    <a class=\"graphic graphic_picture graphicRef56532 \" href=\"UTD.htm?22/60/23494\">",
"     picture 21",
"    </a>",
"    ). The cyst lining may be absent, flattened, or urothelial, and may show differentiation toward mucinous cells. The cytology by definition is bland. The microcystic variant of UC often coexists with the nested variant and is unrelated to primary adenocarcinoma of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/34\">",
"     34",
"    </a>",
"    ]. There is no apparent striking biologic significance associated with this pattern of UC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Micropapillary variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The micropapillary variant of UC is rare. These tumors typically are high-grade, present at an advanced stage, and carry a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. There is a male predominance and the median age of diagnosis is about 70.",
"   </p>",
"   <p>",
"    This rare variant of UC resembles serous carcinoma of the ovary. The surface of the tumors shows slender, delicate papillary and villiform processes, often without a central vascular core (",
"    <a class=\"graphic graphic_picture graphicRef69301 \" href=\"UTD.htm?25/43/26294\">",
"     picture 22",
"    </a>",
"    ). The invasive component is characterized by minute nests of cells or delicate papillae contained within tissue retraction spaces, simulating lymphatic spaces. These tumors invariably invade muscle (",
"    <a class=\"graphic graphic_picture graphicRef69301 \" href=\"UTD.htm?25/43/26294\">",
"     picture 22",
"    </a>",
"    ) and have a high incidence of metastasis. The percentage of micropapillary component has been shown to be a significant adverse prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Lymphoepithelioma-like variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few cases of UC resembling lymphoepithelioma of the nasopharynx have been reported (",
"    <a class=\"graphic graphic_picture graphicRef79184 \" href=\"UTD.htm?16/58/17322\">",
"     picture 23",
"    </a>",
"    ). These tumors show a male predominance and tend to occur in late adulthood. Unlike lymphoepithelioma of the nasopharynx, association with Epstein-Barr virus (EBV) infection has not been documented, either by immunohistochemistry or by in situ hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epithelial tumor cells are large and arranged in syncytia, with individual undifferentiated neoplastic cells with indistinct cell borders, pleomorphic vesicular nuclei, prominent nucleoli and numerous mitoses. The background consists of a prominent lymphoid infiltrate. The differential diagnosis includes malignant lymphoma, poorly differentiated UC with lymphoid stroma, and poorly differentiated squamous cell carcinoma. In limited biopsy material, florid chronic cystitis may be confused with lymphoepithelioma-like carcinoma.",
"   </p>",
"   <p>",
"    When only focal lymphoepithelioma-like carcinoma is present the proportion of lymphoepithelioma-like carcinoma should be reported, and their behavior is similar to conventional UC of the same grade and stage. The lymphoepithelioma-like component is responsive to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Lymphoma-like and plasmacytoid variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the lymphoma-like and plasmacytoid variants of UC, malignant cells resemble those of malignant lymphoma or plasmacytoma (",
"    <a class=\"graphic graphic_picture graphicRef79405 \" href=\"UTD.htm?43/34/44583\">",
"     picture 24",
"    </a>",
"    ). Only a few cases have been reported, most of which contained high-grade UC.",
"   </p>",
"   <p>",
"    The histologic features of these variants are characterized by the presence of discohesive oval to round malignant cells in a loose or myxoid stroma (",
"    <a class=\"graphic graphic_picture graphicRef79405 \" href=\"UTD.htm?43/34/44583\">",
"     picture 24",
"    </a>",
"    ). The tumor cells have eccentrically placed nuclei and abundant eosinophilic cytoplasm. The differential diagnosis includes lymphoma (plasmacytoid type), multiple myeloma, malignant melanoma, metastatic carcinoma, paraganglioma, neuroendocrine carcinoma, and rhabdomyosarcoma. The prognosis of those tumors is poor and related to the pathologic stage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. Most patients have locally advanced disease at presentation. Progression to metastatic disease is frequent and survival tends to be short.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Sarcomatoid variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term sarcomatoid variant of UC should be used for all biphasic malignant neoplasms exhibiting morphologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunohistochemical evidence of both epithelial and mesenchymal differentiation. More than 100 cases have been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3\">",
"     3",
"    </a>",
"    ]. A recent data analysis has shown that approximately 0.6 percent of all bladder carcinomas are sarcomatoid carcinomas and carcinosarcomas. Molecular studies strongly argue for a monoclonal origin of both the epithelial and mesenchymal components in sarcomatoid carcinoma and carcinosarcoma.",
"   </p>",
"   <p>",
"    The mesenchymal component most frequently observed is an undifferentiated high-grade spindle cell neoplasm. The most common heterologous element is osteosarcoma followed by chondrosarcoma (",
"    <a class=\"graphic graphic_picture graphicRef60137 \" href=\"UTD.htm?43/4/44104\">",
"     picture 25",
"    </a>",
"    ), rhabdomyosarcoma, and leiomyosarcoma. Nodal and distant organ metastases at diagnosis are common. Three-quarters of patients are dead of cancer within 48 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/51-55\">",
"     51-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific problems that can arise in the differential diagnosis of UC include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nested variant of UC can be difficult to differentiate from von Brunn's nests. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nested variant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In limited crushed biopsies, florid chronic cystitis may be confused with lymphoepithelioma-like carcinoma. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Lymphoepithelioma-like variant'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The glandular component of UC with glandular differentiation in rare cases raises the possibility of a nephrogenic adenoma.",
"     </li>",
"     <li>",
"      A poorly differentiated bladder cancer in a male should raise the possibility of prostate carcinoma, particularly if the specimen is obtained from the trigone or bladder neck. Immunoperoxidase staining may be very helpful. Positive staining for both CK7 and CK20 favors the diagnosis of UC (",
"      <a class=\"graphic graphic_picture graphicRef69785 \" href=\"UTD.htm?9/62/10215\">",
"       picture 26",
"      </a>",
"      ), while reactivity for PSA and PSAP favors the diagnosis of prostate carcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SQUAMOUS CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinomas (SCCs) of the bladder are derived from the urothelium and characterized by a pure squamous cell phenotype. In North America and Europe, SCCs comprise less than 5 percent of bladder cancers. In contrast, bladder cancer is significantly more common overall and SCCs comprise about 75 percent of cases in areas of the world where Schistosoma haematobium infection is endemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonurothelial bladder cancer\", section on 'Nonschistosomal SCC'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link&amp;anchor=H15#H15\">",
"     \"Nonurothelial bladder cancer\", section on 'Schistosomal bladder cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most SCCs are bulky, polypoid, solid, necrotic masses that fill the bladder lumen. The presence of necrotic material and keratin debris on the surface is typical.",
"   </p>",
"   <p>",
"    SCC of the bladder is morphologically indistinguishable from SCC of other sites. The invasive component may be well differentiated with islands of squamous cells demonstrating keratinization, prominent intercellular bridges, and minimal nuclear pleomorphism (",
"    <a class=\"graphic graphic_picture graphicRef65089 \" href=\"UTD.htm?21/40/22149\">",
"     picture 27",
"    </a>",
"    ). Poorly differentiated tumors are characterized by marked nuclear pleomorphism and only focal evidence of squamous differentiation. The presence of keratinizing squamous metaplasia in the adjacent flat epithelium supports the diagnosis of SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCC often presents at an advanced stage. However, radical cystectomy with lymph node dissection appears to offer a significant benefit in survival in a subset of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinoma of the bladder is characterized histologically by a pure glandular phenotype. These tumors most often are derived from the urothelium of the bladder (\"nonurachal adenocarcinoma\") and less often arise from a remnant of the urachus (\"urachal adenocarcinoma\") [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Nonurachal adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonurachal adenocarcinomas typically occur in the bladder base or dome, but can appear anywhere in the bladder (",
"    <a class=\"graphic graphic_picture graphicRef63219 \" href=\"UTD.htm?34/40/35459\">",
"     picture 28",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonurothelial bladder cancer\", section on 'Nonurachal adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urothelial mucosa is replaced by glandular structures with definite nuclear atypia. Based on histology, the adenocarcinoma of the bladder is subdivided into various subtypes including mucinous (24 percent), enteric (19 percent), signet-ring cell (17 percent), and mixed (13 percent); in 28 percent of cases no specific subtype is specified. The enteric type resembles adenocarcinoma of the colon. Tumors with abundant mucin and tumor cells floating within the mucin are classified as mucinous or colloid type. Adenocarcinoma in situ may be found alone or in combination with invasive adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/3,58\">",
"     3,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Urachal adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urachal adenocarcinoma is derived from remnants of the urachus and thus typically involves the bladder dome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Although the tumor may be discrete, it can involve urachal remnants, forming a large mass in the anterior abdominal wall. Calcified mucinous lesions may be identified on a plain x-ray film of the abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonurothelial bladder cancer\", section on 'Urachal adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical correlation is required to differentiate urachal from nonurachal adenocarcinoma of the bladder. The criteria for diagnosing urachal adenocarcinoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Location in the dome or anterior wall of the bladder",
"     </li>",
"     <li>",
"      Sharp demarcation between tumor and normal surface epithelium",
"     </li>",
"     <li>",
"      Lack of an in situ adenocarcinoma component",
"     </li>",
"     <li>",
"      Adjacent mucosa lacking prominent cystitis glandularis",
"     </li>",
"     <li>",
"      Bulk of tumor is in the bladder wall rather than luminal",
"     </li>",
"     <li>",
"      Exclusion of primary adenocarcinoma located elsewhere that has spread secondarily to the bladder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of bladder adenocarcinoma includes metastatic disease or direct extension, commonly from either the colorectum or prostate. Secondary involvement is more common than a primary lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Metastatic cancers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The immunohistochemical profile of bladder adenocarcinoma is variable and is similar to that of adenocarcinoma of the colon. CK 20 is positive in most bladder adenocarcinomas, while CK 7 positivity is variable. Immunoreactivity for b-catenin has been detected in the majority of colorectal adenocarcinomas secondarily involving the bladder, but not in primary bladder tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SMALL CELL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell carcinoma of the bladder is a malignant, poorly differentiated neuroendocrine neoplasm that mimics small cell carcinoma of the lung. A molecular study has indicated that small cell carcinoma and UC are derived from the same clonal population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/67\">",
"     67",
"    </a>",
"    ]. Therefore, most authors consider small cell carcinoma of the urinary bladder as a special variant of UC. Small cell carcinoma of the urinary bladder is characterized by an aggressive clinical course and poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11366?source=see_link\">",
"     \"Small cell carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small cell carcinomas sometimes present as an isolated polypoid or nodular mass but can extensively infiltrate the bladder wall. The dome and lateral walls of the bladder are the most frequent locations, although it arises in a bladder diverticulum in about 5 percent of cases.",
"   </p>",
"   <p>",
"    The cells are small and uniform, with scant cytoplasm, nuclear molding, and nuclei with finally stippled chromatin and inconspicuous nucleoli. Mitoses may be frequent and apoptosis is common (",
"    <a class=\"graphic graphic_picture graphicRef56613 \" href=\"UTD.htm?34/50/35621\">",
"     picture 29",
"    </a>",
"    ). Approximately one-half of small cell carcinomas are associated with areas of UC and less frequently squamous cell carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef56613 \" href=\"UTD.htm?34/50/35621\">",
"     picture 29",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adenocarcinoma.",
"   </p>",
"   <p>",
"    Most small cell carcinomas express neuronal-specific enolase (NSE) and CD56; chromogranin is seen in about one-third. The differential diagnosis includes metastatic small cell carcinoma from another site, malignant lymphoma, lymphoepithelioma-like carcinoma, plasmacytoid carcinoma, and poorly differentiated UC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     METASTATIC CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary bladder may be involved by direct extension of tumors from adjacent sites or by metastases from a distant site [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27481/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Metastases to the bladder are most frequently identified in the bladder neck and trigone.",
"   </p>",
"   <p>",
"    Secondary tumors account for approximately 15 percent of malignant bladder tumors. Cancers extending from the colon or rectum (",
"    <a class=\"graphic graphic_picture graphicRef78117 \" href=\"UTD.htm?24/16/24841\">",
"     picture 30",
"    </a>",
"    ), prostate, and uterine cervix are most common. Metastatic melanomas, and stomach, breast, and lung cancers are less frequent.",
"   </p>",
"   <p>",
"    The lesions may mimic a primary UC or may manifest as multiple submucosal nodules. Multifocality, prominent vascular involvement, absence of mucosal abnormality, and unusual morphology should raise suspicion of metastatic tumors. Tumors with less characteristic histologic features, such as poorly or undifferentiated high-grade tumors, require immunohistochemical work-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder tumors are classified according to the World Health Organization (WHO) schema. Within the WHO system, urothelial cancer is classified as either low-grade or high-grade based upon the degree of nuclear anaplasia and architectural abnormalities (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The most important element in the pathologic staging of urothelial cancer is the extent of invasion into deeper layers of the bladder and surrounding tissues. This information has major implications for both prognosis and treatment and is incorporated into the tumor node metastasis (TNM) staging system. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathologic tumor staging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common bladder tumor pathologies are urothelial, squamous cell, and adenocarcinoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive urothelial cancer, which is also referred to as transitional cell carcinoma, is characterized by invasion beyond the basement membrane. Urothelial cancer is the most common form of bladder cancer in the United States and Europe. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Invasive urothelial carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Squamous cell carcinomas of the bladder are derived from the urothelium and characterized by a pure squamous cell phenotype. In North America and Europe, squamous cell carcinomas comprise less than 5 percent of bladder cancers. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Squamous cell carcinoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"       \"Nonurothelial bladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adenocarcinoma of the bladder is characterized histologically by a pure glandular phenotype. These tumors, which constitute about 2 percent of bladder cancers, most often are derived from the urothelium of the bladder and less often arise from a remnant of the urachus. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Adenocarcinoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"       \"Nonurothelial bladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Histological typing of urinary tumors, Mostofi FK, Sobin LH, Torloni H (Eds), World Health Organization, Geneva 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/2\">",
"      Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22:1435.",
"     </a>",
"    </li>",
"    <li>",
"     and Genetics of Tumors of the Urinary System and Male Genital Organs. In: World Health Organization Classification of Tumors, Epstein JI, Eble JN, Sesterhenn I, Sauter G (Eds), IARC Press, Lyon, France 2004. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/4\">",
"      Reuter VE. The pathology of bladder cancer. Urology 2006; 67:11.",
"     </a>",
"    </li>",
"    <li>",
"     Epstein JI, Amin MB, Reuter VE. Bladder biopsy interpretation. In: Biopsy Interpretation Series, Lippincott Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     Murphy WM. Tumors of the Kidney, Bladder, and Related Urinary Structures, 3rd, AFIP, Washington DC 1994.",
"    </li>",
"    <li>",
"     Grignon DJ. Neoplasms of the Urinary Bladder. In: Urologic Surgical Pathology, Bostwich DG, Eple NJ (Eds), Mosby, St. Louis 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/8\">",
"      Ro JY, Ayala AG, el-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol 1987; 11:668.",
"     </a>",
"    </li>",
"    <li>",
"     Amin MB, Murphy WM, Reuter VE. Controversies in the pathology of transitional cell carcinoma of the urinary bladder. Part II. In: Reviews of Pathology, Rosen PP, Flechner RE (Eds), ASCP Press, Chicago 1997. p.72.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/10\">",
"      Jimenez RE, Keane TE, Hardy HT, Amin MB. pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol 2000; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/11\">",
"      Larsen MP, Steinberg GD, Brendler CB, Epstein JI. Use of Ulex europaeus agglutinin I (UEAI) to distinguish vascular and \"pseudovascular\" invasion in transitional cell carcinoma of bladder with lamina propria invasion. Mod Pathol 1990; 3:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/12\">",
"      Reuter VE. Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven. J Clin Oncol 2005; 23:6450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/13\">",
"      Murphy WM, Soloway MS. Urothelial dysplasia. J Urol 1982; 127:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/14\">",
"      Amin MB, McKenney JK. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/ International Society of Urological Pathology consensus classification system. Adv Anat Pathol 2002; 9:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/15\">",
"      Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/16\">",
"      Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000; 88:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/17\">",
"      Murphy WM, Busch C, Algaba F. Intraepithelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol Suppl 2000; :67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/18\">",
"      Elliott GB, Moloney PJ, Anderson GH. \"Denuding cystitis\" and in situ urothelial carcinoma. Arch Pathol 1973; 96:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/19\">",
"      Fine SW, Humphrey PA, Dehner LP, et al. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification. J Urol 2005; 174:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/20\">",
"      McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 2003; 16:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/21\">",
"      Magi-Galluzzi C, Epstein JI. Urothelial papilloma of the bladder: a review of 34 de novo cases. Am J Surg Pathol 2004; 28:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/22\">",
"      Ho H, Chen YD, Tan PH, et al. Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience. Urology 2006; 68:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/23\">",
"      Kunze E, Schauer A, Schmitt M. Histology and histogenesis of two different types of inverted urothelial papillomas. Cancer 1983; 51:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/24\">",
"      Cameron KM, Lupton CH. Inverted papilloma of the lower urinary tract. Br J Urol 1976; 48:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/25\">",
"      Summers DE, Rushin JM, Frazier HA, Cotelingam JD. Inverted papilloma of the urinary bladder with granular eosinophilic cells. An unusual neuroendocrine variant. Arch Pathol Lab Med 1991; 115:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/26\">",
"      Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol 2004; 35:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/27\">",
"      Sung MT, Maclennan GT, Lopez-Beltran A, et al. Natural history of urothelial inverted papilloma. Cancer 2006; 107:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/28\">",
"      Pich A, Chiusa L, Formiconi A, et al. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol 2001; 25:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/29\">",
"      Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 1997; 14:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/30\">",
"      L&oacute;pez-Beltr&aacute;n A, Mart&iacute;n J, Garc&iacute;a J, Toro M. Squamous and glandular differentiation in urothelial bladder carcinomas. Histopathology, histochemistry and immunohistochemical expression of carcinoembryonic antigen. Histol Histopathol 1988; 3:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/31\">",
"      Wasco MJ, Daignault S, Zhang Y, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/32\">",
"      Holm&auml;ng S, Johansson SL. The nested variant of transitional cell carcinoma--a rare neoplasm with poor prognosis. Scand J Urol Nephrol 2001; 35:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/33\">",
"      Drew PA, Furman J, Civantos F, Murphy WM. The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol 1996; 9:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/34\">",
"      Leroy X, Leteurtre E, De La Taille A, et al. Microcystic transitional cell carcinoma: a report of 2 cases arising in the renal pelvis. Arch Pathol Lab Med 2002; 126:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/35\">",
"      Johansson SL, Borghede G, Holm&auml;ng S. Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 1999; 161:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/36\">",
"      L&oacute;pez JI, Elorriaga K, Imaz I, Bilbao FJ. Micropapillary transitional cell carcinoma of the urinary bladder. Histopathology 1999; 34:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/37\">",
"      Samaratunga H, Khoo K. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology 2004; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/38\">",
"      Kamat AM, Dinney CP, Gee JR, et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007; 110:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/39\">",
"      Edgerton N, Sirintrapun SJ, Munoz M, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 24 cases. Int J Urol 2011; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/40\">",
"      Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 2006; 37:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/41\">",
"      Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI. Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol 2007; 20:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/42\">",
"      Gulley ML, Amin MB, Nicholls JM, et al. Epstein-Barr virus is detected in undifferentiated nasopharyngeal carcinoma but not in lymphoepithelioma-like carcinoma of the urinary bladder. Hum Pathol 1995; 26:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/43\">",
"      Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol 1995; 103:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/44\">",
"      Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol 1994; 18:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/45\">",
"      Dinney CP, Ro JY, Babaian RJ, Johnson DE. Lymphoepithelioma of the bladder: a clinicopathological study of 3 cases. J Urol 1993; 149:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/46\">",
"      Zukerberg LR, Harris NL, Young RH. Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases. Am J Surg Pathol 1991; 15:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/47\">",
"      Sahin AA, Myhre M, Ro JY, et al. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol 1991; 35:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/48\">",
"      Zhang XM, Elhosseiny A, Melamed MR. Plasmacytoid urothelial carcinoma of the bladder. A case report and the first description of urinary cytology. Acta Cytol 2002; 46:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/49\">",
"      Tamboli P, Amin MB, Mohsin SK, et al. Plasmacytoid variant of non-papillary urothelial carcinoma. Mod Pathol 2000; 13:116A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/50\">",
"      Fritsche HM, Burger M, Denzinger S, et al. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol 2008; 180:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/51\">",
"      Lopez-Beltran A, Pacelli A, Rothenberg HJ, et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 1998; 159:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/52\">",
"      Reuter VE. Sarcomatoid lesions of the urogenital tract. Semin Diagn Pathol 1993; 10:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/53\">",
"      Wright JL, Black PC, Brown GA, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 2007; 178:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/54\">",
"      Torenbeek R, Blomjous CE, de Bruin PC, et al. Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol 1994; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/55\">",
"      Torenbeek R, Hermsen MA, Meijer GA, et al. Analysis by comparative genomic hybridization of epithelial and spindle cell components in sarcomatoid carcinoma and carcinosarcoma: histogenetic aspects. J Pathol 1999; 189:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/56\">",
"      Sarma KP. Squamous cell carcinoma of the bladder. Int Surg 1970; 53:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/57\">",
"      Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 2007; 31:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/58\">",
"      Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991; 67:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/59\">",
"      Gill HS, Dhillon HK, Woodhouse CR. Adenocarcinoma of the urinary bladder. Br J Urol 1989; 64:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/60\">",
"      Johnson DE, Hodge GB, Abdul-Karim FW, Ayala AG. Urachal carcinoma. Urology 1985; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/61\">",
"      Kakizoe T, Matsumoto K, Andoh M, et al. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology 1983; 21:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/62\">",
"      Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol 1984; 131:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/63\">",
"      Whitehead ED, Tessler AN. Carcinoma of the urachus. Br J Urol 1971; 43:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/64\">",
"      Tamboli P, Mohsin SK, Hailemariam S, Amin MB. Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel. Arch Pathol Lab Med 2002; 126:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/65\">",
"      Torenbeek R, Lagendijk JH, Van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998; 32:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/66\">",
"      Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001; 25:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/67\">",
"      Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005; 166:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/68\">",
"      Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology 2000; 36:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27481/abstract/69\">",
"      Silver SA, Epstein JI. Adenocarcinoma of the colon simulating primary urinary bladder neoplasia. A report of nine cases. Am J Surg Pathol 1993; 17:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2967 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27481=[""].join("\n");
var outline_f26_53_27481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bladder anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathologic tumor staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lamina propria invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Muscularis propria invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Vascular Invasion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONINVASIVE UROTHELIAL NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Flat lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Papillary lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Urothelial papilloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Inverted papilloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - PUNLMP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - LGPUC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - HGPUC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INVASIVE UROTHELIAL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Histologic variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Squamous differentiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Glandular differentiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nested variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Microcystic variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Micropapillary variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Lymphoepithelioma-like variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Lymphoma-like and plasmacytoid variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Sarcomatoid variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SQUAMOUS CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pathologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Nonurachal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Urachal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SMALL CELL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      METASTATIC CANCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2967|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/56/20356\" title=\"figure 1\">",
"      Urothelial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2967|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/19/27959\" title=\"picture 1\">",
"      Normal bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/23/42357\" title=\"picture 2\">",
"      Lamina propria invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/37/21076\" title=\"picture 3\">",
"      Muscularis propria invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42296\" title=\"picture 4\">",
"      Adipose tissue invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/21/33111\" title=\"picture 5\">",
"      Vascular invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/12/2247\" title=\"picture 6\">",
"      Normal urothelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/29/6610\" title=\"picture 7A\">",
"      Urothelial dysplasia A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/25/40340\" title=\"picture 7B\">",
"      Urothelial dysplasia B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/14/21731\" title=\"picture 7C\">",
"      Urothelial dysplasia C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/54/25443\" title=\"picture 8\">",
"      Urothelial CIS A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/20/5444\" title=\"picture 9\">",
"      Urothelial CIS B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/58/14243\" title=\"picture 10A\">",
"      Urothelial CIS C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/32/23041\" title=\"picture 10B\">",
"      Urothelial CIS D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/41/23189\" title=\"picture 10C\">",
"      Urothelial CIS E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/56/10118\" title=\"picture 10D\">",
"      Urothelial CIS F",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/42/37538\" title=\"picture 11A\">",
"      Urothelial CIS G",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/55/8050\" title=\"picture 11B\">",
"      Urothelial CIS H",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/42/30377\" title=\"picture 12\">",
"      Urothelial papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/23/9590\" title=\"picture 13\">",
"      Inverted papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/23/22900\" title=\"picture 14\">",
"      PUNLMP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/23/33139\" title=\"picture 15\">",
"      LGPUC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/28/18885\" title=\"picture 16\">",
"      HGPUC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/49/2835\" title=\"picture 17\">",
"      Invasive urothelial carcino",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/21/29017\" title=\"picture 18\">",
"      Invasive UC squamous diff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/22/19814\" title=\"picture 19\">",
"      Invasive UC glandular diff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/11/2231\" title=\"picture 20\">",
"      Invasive UC nested variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/60/23494\" title=\"picture 21\">",
"      Infil UC microcyst variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/43/26294\" title=\"picture 22\">",
"      Infil UC micropap variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/58/17322\" title=\"picture 23\">",
"      Infil UC lymphoepith-like",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/34/44583\" title=\"picture 24\">",
"      Infil UC plasmacytoid var",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/4/44104\" title=\"picture 25\">",
"      Infil UC sarcomatoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/62/10215\" title=\"picture 26\">",
"      Infiltrating UC IHC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/40/22149\" title=\"picture 27\">",
"      Squamous cell ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/40/35459\" title=\"picture 28\">",
"      Nonurachal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/50/35621\" title=\"picture 29\">",
"      Small cell ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/16/24841\" title=\"picture 30\">",
"      Secondary extens metastasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2967|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=related_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11366?source=related_link\">",
"      Small cell carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_53_27482="Smoking and pregnancy";
var content_f26_53_27482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Smoking and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27482/contributors\">",
"     Diana Rodriguez-Thompson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27482/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27482/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27482/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/53/27482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/53/27482/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/53/27482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking during pregnancy is the most important modifiable risk factor associated with adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/1\">",
"     1",
"    </a>",
"    ]. It is associated with 5 percent of infant deaths, 10 of preterm births, and 30 percent of small for gestational age infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, smoking and secondhand smoke exposure increases the risk of infertility, placental abruption, preterm premature rupture of membranes (PPROM), and placenta previa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The scope of this problem, the pathophysiology and clinical effects of smoking on fetal outcome, and current recommendations for smoking cessation during pregnancy will be reviewed here. General issues of substance abuse during pregnancy and smoking cessation in a nonpregnant population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFYING MATERNAL TOBACCO USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pregnant women should be asked about tobacco use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/3\">",
"     3",
"    </a>",
"    ]. In clinical practice, screening for tobacco use is easily initiated by asking the patient if she has ever smoked cigarettes and the assessing the number of cigarettes smoked per day. Research studies often use cotinine levels to evaluate exposure to tobacco smoke because social disapproval of smoking, particularly among pregnant women, may influence the truthfulness of the patient's response to these questions. Cotinine is found in urine, blood, and saliva for two to four days after exposure to tobacco smoke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the known harmful effects of smoking on the health of mothers and their children, it is estimated that 22 to 34 percent of American women of reproductive age smoke cigarettes (range: 10 percent [Utah]--46 percent [West Virginia] [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/2\">",
"     2",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Overall estimates of smoking rates during pregnancy vary based on the method of data collection; the Pregnancy Risk Assessment Monitoring System (PRAMS) survey reported a prevalence of 14 percent in 2005 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/2\">",
"     2",
"    </a>",
"    ]. When analyzed by state, the prevalence of smoking anytime during pregnancy ranged from 6 percent in Utah to 36 percent in West Virginia. Smoking prevalence was highest in women under age 25, women with &le;12 years of education, single women, low income women, American",
"    <span class=\"nowrap\">",
"     Indian/Alaska",
"    </span>",
"    Native women, and nonHispanic white women. The overall rate of smoking during pregnancy declined by 9 percent between 2000 and 2005.",
"   </p>",
"   <p>",
"    The exact prevalence of smoking during pregnancy is difficult to discern, not only because of incomplete records, but also because most studies rely on self-reported smoking behavior and are therefore subject to underreporting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/2\">",
"     2",
"    </a>",
"    ]. The use of biochemical markers, including exhaled carbon monoxide and urinary cotinine, has shown that pregnant women underreport both smoking status and the extent of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Published nondisclosure rates range from 24 to 50 percent.",
"   </p>",
"   <p>",
"    In one study conducted at the University of Alabama, 25 percent of the patients screened reported being smokers. Among self-reported nonsmokers, 24 percent had cotinine levels consistent with active smoking. Thus, the actual prevalence of smoking was 43 percent. About one-half of the nondisclosers reported at their first visit that they had quit smoking after conception. For this reason, targeting patients who report quitting recently may help identify nondisclosers. However, it is possible that those self-reported nonsmokers who were labeled as nondisclosers were actually nonsmokers living with or working with smokers, thus, having high cotinine levels due to constant environmental exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired fetal oxygen delivery is the best-studied cause of adverse outcome in pregnant women who smoke. Pathologic evaluations of the placentas of smokers have shown structural changes, including a reduction in the fraction of capillary volume and increased thickness of the villous membrane when compared to nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Both of these factors may contribute to abnormal gas exchange within the placenta. Exposure to cigarette smoke also acutely decreases intervillous perfusion, possibly via nicotine-induced vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/12\">",
"     12",
"    </a>",
"    ]. However, Doppler studies of uterine and umbilical blood flow in smokers have not reported consistent effects.",
"   </p>",
"   <p>",
"    Another problem is that carbon monoxide exposure from smoking causes the formation of carboxyhemoglobin, which has multiple effects on systemic and fetal oxygen delivery. Carboxyhemoglobin is cleared slowly from the fetal circulation, and diminishes tissue oxygenation via competitive inhibition with oxyhemoglobin and a left-shift of the oxyhemoglobin dissociation curve (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Smoking may also result in direct damage to fetal genetic material. One study compared the chromosomal instability of amniocytes from smokers and non-smokers, and noted an increased incidence of structural chromosomal abnormalities among women who smoked regularly (12 versus 3.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/13\">",
"     13",
"    </a>",
"    ]. Most of these abnormalities were the result of deletions or translocations, and many were localized to the 11q23 region, which is also associated with several hematologic malignancies.",
"   </p>",
"   <p>",
"    Other possible mechanisms responsible for adverse fetal outcomes in mothers who smoke include direct toxicity of the more than 2500 substances found in cigarettes, such as ammonia, polycyclic aromatic hydrocarbons, hydrogen cyanide, vinyl chloride, nitrogen oxide, and carbon monoxide [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In addition, there are over 4000 chemicals in mainstream tobacco smoke, which is drawn through the tobacco column and exits through the mouthpiece during puffing. The number of compounds emitted in tobacco smoke may actually exceed 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models suggest that nicotine can directly impair lung development due to interaction with nicotinic acetylcholine receptors (nAChR). Using a primate model, one group demonstrated abundant expression of nAChR in fetal lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/18\">",
"     18",
"    </a>",
"    ]. In a subsequent study, continuous subcutaneous infusion of nicotine into pregnant rhesus monkeys resulted in significant decreases in lung weight and volume, and an increase in airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/19\">",
"     19",
"    </a>",
"    ]. Prenatal nicotine exposure also can blunt the cardiorespiratory response to postnatal hypoxemia in sheep [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/20\">",
"     20",
"    </a>",
"    ]. Similarly, term human infants with significant cotinine levels at delivery are limited in their ability to maximize and vary their heart rate during the first four hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, exposure to nicotine results in sympathetic activation leading to acceleration of fetal heart rate and a reduction in fetal breathing movement. While the consequences of these changes are not well understood, both of these parameters are used as indicators of fetal well-being in antenatal fetal assessment tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal genotype appears to affect the risk of LBW in cigarette smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/22\">",
"     22",
"    </a>",
"    ]. A study of 741 mothers (174 self-reported ever smokers, 567 never smokers) who delivered singleton infants confirmed a reduction in birth weight and length of gestation in ever smokers (280 grams lower and 0.8 weeks shorter, respectively). In addition, continuous smokers whose genotypes were CYP1A1",
"    <span class=\"nowrap\">",
"     Aa/aa",
"    </span>",
"    (heterozygous and homozygous variants) and GSTT1 (del) had significantly greater reductions in infant birth weight than those with CYP1A1 AA (homozygous wild) or GSTT1 present genotypes (520 versus 252 grams for CYP1A1; 642 versus 285 grams for GSTT1). Another study found that fetal GSTT1 (del) also significantly reduced gestational age-adjusted birth weight in offspring of smoking mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a third study, maternal oxidative stress levels increased significantly as the maternal cotinine levels increased in mothers with null type GSTM1 (glutathione S-transferase M1) or wild type GSTT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/24\">",
"     24",
"    </a>",
"    ]. In this study, fetal cotinine levels were significantly associated with maternal cotinine levels and fetal oxidative stress was associated with fetal cotinine levels.",
"   </p>",
"   <p>",
"    The CYP1A1, GSTM1 and GSTT1 genes were studied because they encode enzymes (eg, aryl hydrocarbon hydroxylase, glutathione S-transferases) active in the body's metabolism and elimination of toxic substances contained in cigarette smoke. These studies suggest that maternal genetic polymorphisms that influence the activity of these enzymes increase",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    susceptibility to the adverse effects of environmental substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative impact of cigarette smoking on fetal health is well established. Cigarette smoking has been associated with numerous adverse outcomes, including spontaneous pregnancy loss, placental abruption, PPROM, placenta previa, preterm labor and delivery, low birth weight (LBW), and ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/25\">",
"     25",
"    </a>",
"    ]. While the pathophysiology is not completely understood, as discussed above, several possible mechanisms related to impaired gas exchange, direct toxicity, and sympathetic activation have been proposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subfertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;As much as 13 percent of subfertility and delay in time to conception has been attributed to smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/25\">",
"     25",
"    </a>",
"    ]. Chemicals in cigarette smoke appear to accelerate follicular depletion and may impede gametogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 12 studies reported the overall OR for risk of infertility in women smokers versus nonsmokers was 1.60 (95% CI 1.34-1.91) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/28\">",
"     28",
"    </a>",
"    ]. Studies of subfertile women undergoing in-vitro fertilization (IVF) treatment also showed a reduction in fecundity among women smokers. The odds of pregnancy per number of IVF-treated cycles was significantly lower in smokers versus nonsmokers: OR 0.66 (95% CI 0.49-0.88). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link&amp;anchor=H7#H7\">",
"     \"Optimizing natural fertility in couples planning pregnancy\", section on 'Tobacco use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Low birth weight and small for gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;LBW (&lt;2500 grams) is the best-studied complication of smoking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    being exposed to second hand smoke during pregnancy. Women who smoke are 1.5 to 3.5 times more likely to have a LBW infant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29-35\">",
"     29-35",
"    </a>",
"    ]. The risk increases with increasing cigarette consumption. Birth weight is influenced greatly by gestational age at delivery, and smoking modestly increases the risk of preterm delivery.",
"   </p>",
"   <p>",
"    However, the effect of smoking on birth weight cannot be explained solely by earlier gestational age at delivery. Smokers have an increased risk of a small for gestational age (SGA) baby with relative risks ranging from 1.3 to 10.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29,30,32,36\">",
"     29,30,32,36",
"    </a>",
"    ]. A case-control study conducted among Italian pregnant women with term deliveries showed that both self-reported active smoking during pregnancy and environmental tobacco smoke exposure were associated with a birth weight less than the 5th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/37\">",
"     37",
"    </a>",
"    ]. Similar to other studies, a dose-response relationship was observed. It has been estimated that if smoking were eliminated in pregnant women, the number of SGA infants would be reduced by 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/38\">",
"     38",
"    </a>",
"    ]. The birth weight deficit associated with smoking is 200 to 300 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29,39,40\">",
"     29,39,40",
"    </a>",
"    ]. There is evidence from observational studies that smoking cessation in the first trimester lowers the rate of SGA births to that of nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of smoking on birth weight seems to be more marked among older women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29\">",
"     29",
"    </a>",
"    ], and independent of race and, possibly, fetal gender. Male fetuses may be more affected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/43\">",
"     43",
"    </a>",
"    ], but this has not been a consistent finding. It has been estimated that at least 20 percent of LBW and SGA infants are attributable to tobacco exposure during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29\">",
"     29",
"    </a>",
"    ]. Smoking during the third trimester appears to have the greatest impact on birth weight, and women who quit smoking by the third trimester have birth weights similar to those of nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/32,44,45\">",
"     32,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Spontaneous pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the association between cigarette smoking and spontaneous pregnancy losses, with conflicting results. While some reports have suggested that smokers may not have an increased risk, there is significant evidence that heavy smoking (&gt;10 cigarettes per day) may be associated with increased pregnancy loss (relative risk 1.2 to 3.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This association is more pronounced when controlling for other causes of pregnancy loss, such as limiting the analysis to chromosomally normal abortuses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. In addition, cigarette smoking has been associated with early pregnancy loss after assisted reproductive technology treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Stillbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it had been thought that cigarette smoking did not increase the risk of stillbirth, defined as fetal death after 28 weeks of gestation, large case control and cohort studies have shown a relative risk ranging from 1.2 to 1.4 in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29,52-55\">",
"     29,52-55",
"    </a>",
"    ]. A dose response curve has been reported, with heavy smokers having the greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/53,56,57\">",
"     53,56,57",
"    </a>",
"    ]. In addition, a prospective study suggested that nonsmoking women passively exposed to secondhand smoke may be at higher risk of intrauterine death than nonexposed women (risk ratio 1.53 95% CI 0.98-2.38) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/58\">",
"     58",
"    </a>",
"    ]. This trend could not be explained by age, previous spontaneous abortion, educational level, planning of pregnancy, or alcohol use. However, most of this risk was confined to first-trimester fetal loss (risk ratio 2.16 95% CI 1.23-3.81), whereas active smoking was associated with intrauterine death later in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a consistent increase in risk of PPROM among smokers, with relative risks ranging from 1.9 to 4.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. The risk persists when controlled for other known risk factors for PPROM, including intrauterine or genitourinary infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Placental abruption/placenta previa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking increases the risk of placental abruption, with reported adjusted relative risks of 1.4 to 2.5. Dose-response curve analysis has consistently revealed that the risk of abruption is greatest among heavy smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Because PPROM is associated with both cigarette smoking and placental abruption, the relationship between cigarette smoking and abruption may be partially explained by the increased risk of PPROM. However, cigarette smoking appears to be a risk factor for placental abruption, independent of PPROM.",
"   </p>",
"   <p>",
"    Cigarette smoking has also been consistently associated with placenta previa, with reported relative risks ranging from 1.4 to 4.4 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/66-72\">",
"     66-72",
"    </a>",
"    ]. A dose-response curve for this complication has not been consistently replicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preterm delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm delivery (&lt;37 weeks of gestation) is a complex variable to study because it represents the final common pathway for numerous conditions during pregnancy. Preterm delivery may be the consequence of idiopathic premature labor or may be secondary to complications of pregnancy such as preeclampsia, preterm PROM, chorioamnionitis, or placental abruption (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women who smoke are 1.3 to 2.5 times more likely to have a preterm delivery, particularly one prior to 32 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/1,31,73-76\">",
"     1,31,73-76",
"    </a>",
"    ]. The relative risk is highest among women with no known risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/1\">",
"     1",
"    </a>",
"    ]. Most important, cigarette smoking and drug use are often the only potentially modifiable risk factors associated with premature birth. There is evidence from observational studies that smoking cessation in the first trimester lowers the rate of preterm delivery to that of nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, it's plausible that smoking may increase the risk of congenital abnormalities due to fetal exposure to over 2500 chemicals found in cigarette smoke. As an example, the vasoactive effects of nicotine may result in vascular disruption and the subsequent development of malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It remains unclear, however, whether smoking actually increases the risk of congenital malformations. Although the overall rate of congenital malformations may not be higher among smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/77-81\">",
"     77-81",
"    </a>",
"    ], smoking may contribute to the risk of anomalies associated with focal vascular disruption, including cleft lip with or without cleft palate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/80,82-89\">",
"     80,82-89",
"    </a>",
"    ], gastroschisis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/90\">",
"     90",
"    </a>",
"    ], anal atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/91\">",
"     91",
"    </a>",
"    ], transverse limb reduction defects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/92,93\">",
"     92,93",
"    </a>",
"    ], cardiac defects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/94\">",
"     94",
"    </a>",
"    ], digital anomalies (polydactyly, syndactyly, or adactyly) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/95\">",
"     95",
"    </a>",
"    ], and bilateral renal agenesis or hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/96\">",
"     96",
"    </a>",
"    ]. Although a number of studies have shown a possible association, these results have not been consistently replicated. There is evolving evidence that genetic factors may modify this risk, such that smoking may increase the risk only in individuals who are carriers of specific genotypes, including polymorphisms of the transforming growth factor-alpha locus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29,81,85\">",
"     29,81,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7469948\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is associated with decreased milk volume production, lower milk fat concentration, and consequently, shorter duration of lactation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/97-103\">",
"     97-103",
"    </a>",
"    ]. Breast-fed infants of smoking mothers slept less when fed after their mothers smoked recently than when she had abstained [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/104\">",
"     104",
"    </a>",
"    ]. They have urinary cotinine levels up to 10-fold higher than bottle-fed infants of smoking mothers, and up to 50 times higher than infants of nonsmoking mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Postnatal morbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of neonatal death (death within 28 days of birth) appears to be increased in smokers, with a relative risk ranging from 1.2 to 1.4 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29,52,54,106\">",
"     29,52,54,106",
"    </a>",
"    ]. Other postnatal morbidities that have been associated with maternal smoking include sudden infant death syndrome (SIDS), respiratory infections (eg, bronchitis, pneumonia), asthma, atopy, otitis media, infantile colic, bronchiolitis, short stature, lower reading and spelling scores, shorter attention spans, hyperactivity, childhood obesity, and decreased school performance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/15,107-113\">",
"     15,107-113",
"    </a>",
"    ]. However, studies that have adjusted for measured and unmeasured confounders have often found these adverse outcomes are not present or are related to familial factors associated with maternal smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sudden infant death syndrome (SIDS) has been consistently associated with maternal smoking. Among children who are exposed either in utero or during postnatal life, the relative risk of SIDS ranges from 2.0 to 7.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. It has been suggested that prenatal exposure is a greater risk factor than infant exposure to secondary smoke at home [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/117\">",
"     117",
"    </a>",
"    ]. Smoking also increases other known risk factors for SIDS such as preterm birth and low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have raised the possibility that cigarette smoking increases the risk of type 2 diabetes in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. While a definitive causal association has not been established, a relationship between cigarette smoking and diabetes mellitus is biologically plausible. In addition, data from the British National Child Development Study suggested that heavy maternal smoking during pregnancy was associated with an increased risk of type 2 diabetes in offspring at 33 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal smoking may have long-term implications for the reproductive health of offspring exposed in utero. Adult males exposed to smoking in utero appear to have a 20 percent reduction in sperm concentration and a 25 percent reduction in total sperm count compared to unexposed men [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/122\">",
"     122",
"    </a>",
"    ]. A possible relationship with reduced fertility in prenatally exposed females has also been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/123-126\">",
"     123-126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal smoking in pregnancy appears to affect cardiovascular risk factors in offspring. In two studies, parental smoking during pregnancy was an independent risk factor for lower HDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/127\">",
"     127",
"    </a>",
"    ], increased carotid artery intima-media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/128\">",
"     128",
"    </a>",
"    ], and lower arterial wall distensibility in offspring aged 5 to 8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/128\">",
"     128",
"    </a>",
"    ]. The long-term clinical implications of these findings are unknown.",
"   </p>",
"   <p>",
"    Finally, maternal smoking has been implicated in an increased susceptibility to cancer in the offspring. In a rat model exposed to prenatal smoking, reduced levels of cytotoxic T-lymphocyte activity and decreased resistance to transplanted tumor cells were demonstrated providing a plausible mechanism for such an effect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Maternal health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal risks related to smoking and the benefits of smoking cessation are discussed separately. There are 30 reported cases of pregnancy associated lung cancer; 17 women had a smoking history, the history was negative in six and unknown in seven [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/130\">",
"     130",
"    </a>",
"    ]. Metastases to the placenta and fetus have also been reported (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREECLAMPSIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analysis has shown that maternal cigarette smoking is associated with a significant reduction in the risk of preeclampsia (OR 0.51, 95% CI 0.37-0.63) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/131\">",
"     131",
"    </a>",
"    ]. This benefit does not outweigh the multiple medical and obstetrical risks associated with smoking during pregnancy. Based on an in vitro experiment, the mechanism may be that cigarette smoke reduces fms-like tyrosine kinase-1 (sFlt-1) and increases placental growth factor (PlGF), which is the opposite of the changes observed in women who develop preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SMOKING CESSATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survey data indicate that 45 percent of pregnant smokers completely stop smoking by the end of pregnancy; quit rates are highest in those groups with the lowest prepregnancy prevalences of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/133\">",
"     133",
"    </a>",
"    ]. Most women who quit tend to stop smoking prior to their first prenatal visit. These relationships were illustrated in a survey conducted in Sweden, in which 32 percent of the pregnant population reported smoking at the time of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/134\">",
"     134",
"    </a>",
"    ]. Only 29 percent of smokers stopped smoking completely during pregnancy: 18 percent prior to the first visit, 7 percent between 10 and 24 weeks, and 4 percent in the third trimester. Similar results were reported in a survey of American women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/135\">",
"     135",
"    </a>",
"    ]. Thus, women still smoking after their first prenatal visit are likely to continue smoking during pregnancy.",
"   </p>",
"   <p>",
"    Risk factors for continued smoking during pregnancy include lower education status (less than high school level), heavy smoking (&gt;10 cigarettes per day), and having a partner who smokes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29,136-139\">",
"     29,136-139",
"    </a>",
"    ]. Additional factors that have been implicated include public insurance, poor coping skills, multiparity, exposure to secondhand smoke at home, and coexisting emotional or psychiatric problems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/134,137,140-142\">",
"     134,137,140-142",
"    </a>",
"    ]. Because many of these factors are interrelated, their independent effects are difficult to discern [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy provides a unique opportunity for medical intervention. Pregnant women who smoke should be identified at the first prenatal visit. Women seeking prenatal care see their physicians frequently during their pregnancy, allowing for multiple opportunities to assess and reinforce abstinence. For some women, pregnancy is the only time they seek medical attention. Concerns over the dangers of cigarette smoking for the fetus serve as an additional motivator.",
"   </p>",
"   <p>",
"    All pregnant women who use tobacco should be provided augmented, pregnancy-tailored counseling regarding smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/3\">",
"     3",
"    </a>",
"    ]. Data from meta-analyses of randomized trials show that healthcare provider initiated interventions can lead to significant reductions in the number of women smoking during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/144,145\">",
"     144,145",
"    </a>",
"    ], although counseling alone is associated with only modest improvement in continued abstinence 6 to 12 months after the quit date [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/146\">",
"     146",
"    </a>",
"    ]. Examples of brief interventions include information about smoking related risks from the physician and frequent follow-up to assess patient progress, as well as use of a pregnancy specific or other self help manual, one or more sessions with a health educator, and video tapes on smoking risks and cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis reported pregnant women who received a specific smoking cessation intervention were significantly more likely to stop smoking than women who received information about the risks of smoking in pregnancy and were advised to quit as part of usual care; the absolute difference between groups was 6 per 100 women [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/145\">",
"       145",
"      </a>",
"      ]. Interventions consisted of cognitive behavior therapy, interventions based on stages of change, maternal feedback on fetal health status or measurement of smoking by-products, provision of",
"      <span class=\"nowrap\">",
"       rewards/incentives,",
"      </span>",
"      pharmacotherapy, other (eg, hypnosis). In addition, women who received a smoking cessation intervention had significantly fewer preterm births (RR 0.86, 95%CI 0.74-0.98) and infants with higher mean birthweight (mean difference 39 g, 95% CI 16-63 g) than the usual care group. The most effective intervention appeared to be providing incentives, which helped about 24 percent of women to quit smoking during pregnancy and was associated with a mean increase in birthweight of 124 g.",
"     </li>",
"     <li>",
"      A meta-analysis of randomized trials of efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers found that pharmacotherapy (patch or gum) increased smoking cessation compared with no pharmacotherapy (RR 1.48, 95% CI 1.04-2.09) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/147\">",
"       147",
"      </a>",
"      ]. Treatment ranged from 6 to 12 weeks and post-treatment follow-up ranged from 12 to 26 weeks. Meta-analysis of birth outcomes was not performed; intervention did not have a consistent effect on birth weight or preterm birth rate.",
"      <br/>",
"      <br/>",
"      There were several limitations to these trials, including small numbers of subjects, relatively short periods of follow-up, lack of biochemical validation of abstinence in one of the trials, publication bias, and significant heterogeneity. The authors identified only one study that evaluated the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      on abstinence rates [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/148\">",
"       148",
"      </a>",
"      ]. While a benefit was noted (RR 3.33, 95% CI 1.06-10.49), the study was small, non-randomized, and relied only on self-reported abstinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite evidence that brief interventions work, it is estimated that only 49 percent of obstetricians routinely advise and provide follow-up for smoking cessation; furthermore, only 28 percent discuss actual strategies for cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/136\">",
"     136",
"    </a>",
"    ]. The value of a self-directed smoking cessation program is less clear. In a well-designed study of 1527 women randomly assigned to standard care or an intervention consisting of self-help booklets, there was no difference in the rate of smoking cessation (determined by urinary cotinine levels) between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barriers to cessation, attitudes to nicotine patch use, and perceptions of cessation counseling among pregnant women have been studied using focus groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/149\">",
"     149",
"    </a>",
"    ]. Reasons given for continuing to smoke in pregnancy were skepticism about smoking-related harms, addiction to nicotine, and the smoking behavior of partners",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family members. Most women considered use of nicotine patches acceptable; however, some expressed doubt of patch safety, believing continued smoking was preferable. The women noted that care providers differed in their approaches to smoking cessation and that some no longer asked about smoking status after they reported \"cutting down.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Clinical Practice Guidelines released by the United States Department of Health and Human Services (USDHHS) made three recommendations for treating tobacco use during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Offer psychosocial intervention",
"      </strong>",
"      &mdash; Because of the serious risks of smoking to the pregnant smoker and the fetus, pregnant smokers should, whenever possible, be offered extended or augmented psychosocial interventions that exceed minimal advice to quit. (Strength of evidence = A)",
"      <br/>",
"      <br/>",
"      A meta-analysis conducted by the USDHHS found that abstinence rates were higher in patients in the augmented intervention group when compared to those who received usual care, defined as no counseling or minimal care (less than three minutes) (16.8 versus 6.6 percent, estimated odds ratio of 2.8). These augmented interventions did not require a lot of physician time. Interventions found to be effective generally involved advice from health providers regarding risks (two to five minutes), pregnancy-specific self-help materials, and follow-up. Some of the interventions included a 10 to 15 minute counseling session with a health educator. The recommended total contact time is 5 to 15 minutes, along with availability of self-help material [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Offer intervention throughout pregnancy",
"      </strong>",
"      &mdash; Although abstinence early in pregnancy will produce the greatest benefits to the fetus and mother, quitting at any point in pregnancy can yield benefits. Thus, clinicians should offer effective smoking cessation interventions to pregnant smokers at the first prenatal visit as well as throughout the course of pregnancy. (Strength of evidence = B)",
"      <br/>",
"      <br/>",
"      A reduction in the number of cigarettes smoked during pregnancy has not produced consistent improvement in perinatal outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/73,144\">",
"       73,144",
"      </a>",
"      ]. This finding, in conjunction with concerns that women who reduce the number of cigarettes smoked may compensate by inhaling deeper, has led to the recommendation that smoking cessation, not a reduction in the number of cigarettes smoked, should be the primary outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/138\">",
"       138",
"      </a>",
"      ]. However, it is likely that nondisclosure underestimates the effects of \"cutting down.\" A placebo controlled randomized trial of nicotine gum for smoking cessation during pregnancy reported similar quit rates in both the active drug and placebo groups; however, women in the nicotine gum group smoked fewer cigarettes, had lower cotinine levels, and higher birth weights than those in the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/151\">",
"       151",
"      </a>",
"      ]. These findings support the recommendation that women who are unable to quit smoking should still be encouraged to reduce the number of cigarettes they smoke each day.",
"     </li>",
"     <li>",
"      <strong>",
"       Offer pharmacotherapy",
"      </strong>",
"      &mdash; Pharmacotherapy should be considered when a pregnant woman is otherwise unable to quit, and when the likelihood of quitting, with its potential benefits, outweighs the risks of the pharmacotherapy and potential continued smoking. (Strength of evidence = C)",
"      <br/>",
"      <br/>",
"      Randomized, controlled trials in nonpregnant patients have demonstrated that the use of adjunct pharmacotherapy substantially increases quit rates when compared with placebo. Current practice guidelines by the Agency of Health Care Policy and Research, and the American Psychiatric Association, advocate the use of adjunct pharmacotherapy for all smokers unless contraindicated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/7,152,153\">",
"       7,152,153",
"      </a>",
"      ], whereas the US Preventive Task Force found inadequate evidence to evaluate the safety or efficacy of pharmacotherapy during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/3\">",
"       3",
"      </a>",
"      ]. These therapies remain underutilized, particularly in pregnant patients due to concern over the potential for adverse fetal effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The cost of smoking cessation agents may also be an issue, given smoking prevalence is highest in low income women. Of note, Medicaid programs in several states cover the cost of tobacco-dependence medications and counseling [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nicotine replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been much concern about using nicotine during pregnancy because of known toxicity. In animal models, nicotine increases vascular resistance and reduces uterine blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. Chronic prenatal exposure to nicotine in these models results in abnormal secretion of neurochemical mediators in the brain as well as pathologic behavior within the offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/156\">",
"     156",
"    </a>",
"    ]. Human data show that exposure to cigarettes or to nicotine chewing gum results in a state of sympathetic activation.",
"   </p>",
"   <p>",
"    Nicotine is classified as a class D drug, indicating that there is positive evidence of human risk in pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/14\">",
"     14",
"    </a>",
"    ]. However, there is no strong evidence that pregnant smokers who use nicotine replacement therapy are at higher risk of adverse perinatal events than pregnant smokers not using this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/157\">",
"     157",
"    </a>",
"    ]. Proponents of using nicotine replacement therapy during pregnancy argue that blood levels of nicotine are lower than those achieved during active smoking. In addition, use of nicotine replacement therapy avoids exposure to the other potentially toxic chemicals found in cigarettes. Finally, some argue that it is only for temporary use as a means to achieving smoking cessation, so that the potential benefits outweigh the potential risks.",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) advocates targeting pregnant women for smoking cessation. For women with clear resolve to quit smoking, ACOG states the use of nicotine replacement therapy can be undertaken with close supervision and after a thorough discussion about the risks of continued smoking and the possible risks of replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/109\">",
"     109",
"    </a>",
"    ]. This statement, despite known adverse fetal effects of nicotine, demonstrates acknowledgment of both the importance of smoking on fetal outcomes and the benefit of adjunct pharmacotherapy on smoking cessation in nonpregnant individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, although nicotine replacement therapy appears to be an effective technique for facilitating smoking cessation in the general population, a meta-analysis of randomized trials in pregnant smokers did not demonstrate significantly increased abstinence rates during pregnancy in patch or gum users compared to controls (RR 1.33, 95% CI 0.93-1.91, 6 trials, 1745 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/159\">",
"     159",
"    </a>",
"    ]. This has been attributed to poor rates of adherence to therapy: in one large trial, for example, only 7 percent of patients in the intervention group adhered to nicotine replacement for more than one month [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/160\">",
"     160",
"    </a>",
"    ]. Therefore, pharmacotherapy should not be considered a substitute for psychosocial intervention. Behavioral counseling on an ongoing basis is important and may enhance adherence to nicotine replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/161,162\">",
"     161,162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no information specifically on use of nicotine replacement productions during labor. Based on available information on the physiological effects of these drugs on mother and fetus, there should be no additional risk from continuing their use intrapartum in women who used them antepartum. In addition, they may be useful to reduce nicotine withdrawal symptoms in heavy smokers who are uncomfortable when hospitalization forces them to abstain from smoking. Nicotine is a vasoactive substance, thus both smoking and use of nicotine replacement products are of particular concern in pregnant women with certain pregnancy complications, such as preeclampsia and abruptio placentae, as well as those with medical disorders that are adversely affected by nicotine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bupropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    has been available specifically for smoking cessation since 1998. This treatment option has several advantages over nicotine that are relevant to pregnant women. A well-conducted, randomized controlled trial demonstrated that treatment of nonpregnant individuals with bupropion resulted in higher abstinence rates when compared with placebo and nicotine patch alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/163\">",
"     163",
"    </a>",
"    ]. The addition of nicotine did not significantly increase abstinence rates compared to treatment with bupropion alone.",
"   </p>",
"   <p>",
"    In one of the first prospective, matched, controlled observational studies among pregnant women, pregnant smokers receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    were significantly more likely to quit than pregnant controls (45 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there may be an increase in risk of congenital anomalies with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    in the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H29#H29\">",
"     \"Depression in pregnant women: Management\", section on 'Bupropion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1260650532\">",
"    <span class=\"h2\">",
"     Varenicline",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no information on the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    use in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the above limitations, pharmacotherapy has not been recommended for all women during pregnancy but is primarily targeted for women who are unlikely to quit. The strength of the evidence was rated as C, indicating that it is an important clinical scenario in which the expert panel achieved consensus despite absence of randomized controlled trials. Given the known benefits of smoking cessation during pregnancy, it appears reasonable to offer pharmacotherapy to pregnant women who are at high risk for continued smoking: heavy smokers (&gt;10 cigarettes per day); those smoking later in pregnancy; and those who have attempted to stop previously.",
"   </p>",
"   <p>",
"    General principles of prescribing drugs during pregnancy should be followed. These include using the lowest dose necessary to achieve success in order to minimize fetal exposure and, if possible, delaying therapy until the second trimester in order to avoid the period of embryogenesis when the fetus is most sensitive to teratogens.",
"   </p>",
"   <p>",
"    The five A's (ask, advise, assess, assist, and arrange) have been adopted by different agencies such as the National Cancer Institute and the Agency for Health Care Policy and Research. The strategies outlined in the table are derived from the Clinical Practice Guidelines published by the United States Department of Health and Human Services, and have subsequently been modified by various authors for use during pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50450 \" href=\"UTD.htm?14/40/14990\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/7,150,164\">",
"     7,150,164",
"    </a>",
"    ]. The specific action steps outlined have been gathered from various investigators and guideline panels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POSTPARTUM RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nonpregnant patients, those who are smoke-free for over six months are more likely to be abstinent long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/154\">",
"     154",
"    </a>",
"    ]. Although many pregnant women can remain smoke-free during their entire pregnancy, the Pregnancy Risk Assessment Monitoring System (PRAMS) reported relapse rates of 42, 61, and 67 percent at 2 to 3, 4 to 5, and &ge;6 months postpartum, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/165\">",
"     165",
"    </a>",
"    ]. Similarly, a study from the UK reported 47 percent of women who had quit smoking during pregnancy relapsed within the first six weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/166\">",
"     166",
"    </a>",
"    ]. Breastfeeding appears to reduce the risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/166-168\">",
"     166-168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The postpartum period is a period of great stress and emotional fluctuations, and lack of both social supports and coping skills have been implicated in relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/169,170\">",
"     169,170",
"    </a>",
"    ]. Lower mood scores have also been strongly associated with smoking relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/171,172\">",
"     171,172",
"    </a>",
"    ]. About 50 to 70 percent of postpartum women report transient depressed mood or postpartum blues, making them vulnerable to relapse during this time. Women who relapse are more likely to have family members or friends who smoke and report less social support [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/173\">",
"     173",
"    </a>",
"    ]. Relapsers are also more likely to report lower confidence for staying smoke-free. Interestingly, studies looking at process of change variables have demonstrated that women who quit during pregnancy are more likely to see their quitting as temporary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/174\">",
"     174",
"    </a>",
"    ]. There are no known effective strategies for preventing postpartum relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/173,175\">",
"     173,175",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SECONDHAND SMOKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to secondhand smoke during pregnancy also appears to have adverse effects on the fetus, child, and adult [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/176-179\">",
"     176-179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2011 meta-analysis of 19 studies that assessed the effects of secondhand smoke exposure on nonsmoking pregnant women, exposure to cigarette smoke significantly increased the risk of stillbirth (OR 1.23, 95% CI 1.09-1.38; four studies) and congenital malformations (OR 1.13, 95% CI 1.01-1.26; seven studies), although none of the associations with specific congenital abnormalities were individually significant [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/176\">",
"       176",
"      </a>",
"      ]. Secondhand smoke exposure had no significant effect on risk of miscarriage or perinatal or neonatal death.",
"     </li>",
"     <li>",
"      In a 2008 meta-analysis by the same authors, secondhand smoke exposure in nonsmoking pregnant women reduced mean birth weight by 33 g or more, and increased the risk of birth weight below 2500 g by 22 percent, but had no clear effect on gestation or the risk of being small for gestational age [",
"      <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a study of the incidence of preterm delivery in the Belgian population after implementation of smoke-free legislation in 2006, 2007, and 2010 noted a significant reduction in preterm birth after the introduction of each phase of the smoking ban, this finding was likely due to chance or confounders since the smoking bans had no significant effect on birth weight (mean birth weight, low birth weight, or small for gestational age infant), which is more strongly correlated with smoking than preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/53/27482/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of secondhand smoke on children and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link\">",
"     \"Control of secondhand smoke exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43969?source=see_link\">",
"       \"Patient information: Smoking in pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=see_link\">",
"       \"Patient information: Secondhand smoke: Risks to children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who smoke or are exposed to secondhand smoke during pregnancy are at greater risk for spontaneous pregnancy losses, preterm delivery, low birth weight, PPROM, placenta previa, abruptio placentae, and stillbirth. Most of these risks are reduced by smoking cessation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although smoking cessation during pregnancy is of maximal benefit if it occurs early in the first trimester, quitting at any time during pregnancy can have some beneficial effects. For women unable to quit smoking, reducing the number of cigarettes smoked still has maternal and fetal benefits. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Smoking cessation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short behavioral and educational interventions tailored for the pregnant woman are associated with higher cessation rates. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'General guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacotherapy is recommended for women who are heavy smokers and are unable to quit on their own. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'General guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpartum relapse is a significant problem, with about 50 percent of quitters relapsing in the first two months after delivery. These women should be considered \"at risk\" and provided ongoing support. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Postpartum relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/1\">",
"      Heffner LJ, Sherman CB, Speizer FE, Weiss ST. Clinical and environmental predictors of preterm labor. Obstet Gynecol 1993; 81:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/2\">",
"      Tong VT, Jones JR, Dietz PM, et al. Trends in smoking before, during, and after pregnancy - Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000-2005. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/3\">",
"      U.S. Preventive Services Task Force. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009; 150:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/4\">",
"      Garrett BE, Dube SR, Trosclair A. Cigarette Smoking &mdash; United States, 1965&ndash;2008. MMWR Morb Mortal Wkly Rep 2011; 60:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/5\">",
"      Kendrick JS, Zahniser SC, Miller N, et al. Integrating smoking cessation into routine public prenatal care: the Smoking Cessation in Pregnancy project. Am J Public Health 1995; 85:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/6\">",
"      Windsor RA, Lowe JB, Perkins LL, et al. Health education for pregnant smokers: its behavioral impact and cost benefit. Am J Public Health 1993; 83:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/7\">",
"      Windsor RA, Woodby LL, Miller TM, et al. Effectiveness of Agency for Health Care Policy and Research clinical practice guideline and patient education methods for pregnant smokers in medicaid maternity care. Am J Obstet Gynecol 2000; 182:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/8\">",
"      Moore L, Campbell R, Whelan A, et al. Self help smoking cessation in pregnancy: cluster randomised controlled trial. BMJ 2002; 325:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/9\">",
"      Burton GJ, Palmer ME, Dalton KJ. Morphometric differences between the placental vasculature of non-smokers, smokers and ex-smokers. Br J Obstet Gynaecol 1989; 96:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/10\">",
"      Larsen LG, Clausen HV, J&oslash;nsson L. Stereologic examination of placentas from mothers who smoke during pregnancy. Am J Obstet Gynecol 2002; 186:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/11\">",
"      Bush PG, Mayhew TM, Abramovich DR, et al. A quantitative study on the effects of maternal smoking on placental morphology and cadmium concentration. Placenta 2000; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/12\">",
"      Lehtovirta P, Forss M. The acute effect of smoking on intervillous blood flow of the placenta. Br J Obstet Gynaecol 1978; 85:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/13\">",
"      de la Chica RA, Ribas I, Giraldo J, et al. Chromosomal instability in amniocytes from fetuses of mothers who smoke. JAMA 2005; 293:1212.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs, GG, Freeman, RK, Yaffe, SJ. Drugs in Lactation and Pregnancy. Williams &amp; Wilkins, Baltimore, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/15\">",
"      Brown, HL, Hopf, SK. Clinical perspectives on smoking during pregnancy. Female Patient 1998; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/16\">",
"      Tuthill DP, Stewart JH, Coles EC, et al. Maternal cigarette smoking and pregnancy outcome. Paediatr Perinat Epidemiol 1999; 13:245.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Profiles: Tobacco Related Exposures, Report on Carcinogens, 11th ed, US Department of Health and Human Services, Public Health Service, National Toxicology Program. file://.ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s176toba.pdf. (Accessed on 10/19/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/18\">",
"      Sekhon HS, Jia Y, Raab R, et al. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. J Clin Invest 1999; 103:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/19\">",
"      Sekhon HS, Keller JA, Benowitz NL, Spindel ER. Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am J Respir Crit Care Med 2001; 164:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/20\">",
"      Hafstr&ouml;m O, Milerad J, Sundell HW. Prenatal nicotine exposure blunts the cardiorespiratory response to hypoxia in lambs. Am J Respir Crit Care Med 2002; 166:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/21\">",
"      Sherman J, Young A, Sherman MP, et al. Prenatal smoking and alterations in newborn heart rate during transition. J Obstet Gynecol Neonatal Nurs 2002; 31:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/22\">",
"      Wang X, Zuckerman B, Pearson C, et al. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. JAMA 2002; 287:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/23\">",
"      Aagaard-Tillery K, Spong CY, Thom E, et al. Pharmacogenomics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes. Obstet Gynecol 2010; 115:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/24\">",
"      Park EY, Hong YC, Lee KH, et al. Maternal exposure to environmental tobacco smoke, GSTM1/T1 polymorphisms and oxidative stress. Reprod Toxicol 2008; 26:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/25\">",
"      Practice Committee of the American Society for Reproductive Medicine. Smoking and infertility: a committee opinion. Fertil Steril 2012; 98:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/26\">",
"      Zenzes MT. Smoking and reproduction: gene damage to human gametes and embryos. Hum Reprod Update 2000; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/27\">",
"      Zenzes MT, Wang P, Casper RF. Cigarette smoking may affect meiotic maturation of human oocytes. Hum Reprod 1995; 10:3213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/28\">",
"      Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic review and meta-analysis. Hum Reprod 1998; 13:1532.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. Women and Smoking: A Report of the Surgeon General. Rockville: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/30\">",
"      Spinillo A, Capuzzo E, Nicola SE, et al. Factors potentiating the smoking-related risk of fetal growth retardation. Br J Obstet Gynaecol 1994; 101:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/31\">",
"      McDonald AD, Armstrong BG, Sloan M. Cigarette, alcohol, and coffee consumption and prematurity. Am J Public Health 1992; 82:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/32\">",
"      Lieberman E, Gremy I, Lang JM, Cohen AP. Low birthweight at term and the timing of fetal exposure to maternal smoking. Am J Public Health 1994; 84:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/33\">",
"      Cigarette smoking and the risk of low birth weight: a comparison in black and white women. Alameda County Low Birth Weight Study Group. Epidemiology 1990; 1:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/34\">",
"      Centers for Disease Control (CDC). Effects of maternal cigarette smoking on birth weight and preterm birth--Ohio, 1989. MMWR Morb Mortal Wkly Rep 1990; 39:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/35\">",
"      Eskenazi B, Prehn AW, Christianson RE. Passive and active maternal smoking as measured by serum cotinine: the effect on birthweight. Am J Public Health 1995; 85:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/36\">",
"      Aagaard-Tillery KM, Porter TF, Lane RH, et al. In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth. Am J Obstet Gynecol 2008; 198:66.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/37\">",
"      Fantuzzi G, Vaccaro V, Aggazzotti G, et al. Exposure to active and passive smoking during pregnancy and severe small for gestational age at term. J Matern Fetal Neonatal Med 2008; 21:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/38\">",
"      Rasmussen S, Irgens LM. The effects of smoking and hypertensive disorders on fetal growth. BMC Pregnancy Childbirth 2006; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/39\">",
"      Ellard GA, Johnstone FD, Prescott RJ, et al. Smoking during pregnancy: the dose dependence of birthweight deficits. Br J Obstet Gynaecol 1996; 103:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/40\">",
"      Secker-Walker RH, Vacek PM, Flynn BS, Mead PB. Estimated gains in birth weight associated with reductions in smoking during pregnancy. J Reprod Med 1998; 43:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/41\">",
"      Polakowski LL, Akinbami LJ, Mendola P. Prenatal smoking cessation and the risk of delivering preterm and small-for-gestational-age newborns. Obstet Gynecol 2009; 114:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/42\">",
"      McCowan LM, Dekker GA, Chan E, et al. Spontaneous preterm birth and small for gestational age infants in women who stop smoking early in pregnancy: prospective cohort study. BMJ 2009; 338:b1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/43\">",
"      Varvarigou AA, Asimakopoulou A, Beratis NG. Impact of maternal smoking on birth size: effect of parity and sex dimorphism. Neonatology 2009; 95:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/44\">",
"      Bernstein IM, Mongeon JA, Badger GJ, et al. Maternal smoking and its association with birth weight. Obstet Gynecol 2005; 106:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/45\">",
"      Prabhu N, Smith N, Campbell D, et al. First trimester maternal tobacco smoking habits and fetal growth. Thorax 2010; 65:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/46\">",
"      Dom&iacute;nguez-Rojas V, de Juanes-Pardo JR, Astasio-Arbiza P, et al. Spontaneous abortion in a hospital population: are tobacco and coffee intake risk factors? Eur J Epidemiol 1994; 10:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/47\">",
"      Armstrong BG, McDonald AD, Sloan M. Cigarette, alcohol, and coffee consumption and spontaneous abortion. Am J Public Health 1992; 82:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/48\">",
"      Kline J, Levin B, Kinney A, et al. Cigarette smoking and spontaneous abortion of known karyotype. Precise data but uncertain inferences. Am J Epidemiol 1995; 141:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/49\">",
"      Alberman E, Creasy M, Elliott M, Spicer C. Maternal factors associated with fetal chromosomal anomalies in spontaneous abortions. Br J Obstet Gynaecol 1976; 83:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/50\">",
"      Bou&eacute; J, Lazar P. Retrospective and prospective epidemiological studies of 1500 karyotyped spontaneous human abortions. Teratology 1975; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/51\">",
"      Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod 2002; 17:3220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/52\">",
"      Schramm WF. Smoking during pregnancy: Missouri longitudinal study. Paediatr Perinat Epidemiol 1997; 11 Suppl 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/53\">",
"      Raymond EG, Cnattingius S, Kiely JL. Effects of maternal age, parity, and smoking on the risk of stillbirth. Br J Obstet Gynaecol 1994; 101:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/54\">",
"      Cnattingius S, Haglund B, Meirik O. Cigarette smoking as risk factor for late fetal and early neonatal death. BMJ 1988; 297:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/55\">",
"      Burguet A, Kaminski M, Abraham-Lerat L, et al. The complex relationship between smoking in pregnancy and very preterm delivery. Results of the Epipage study. BJOG 2004; 111:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/56\">",
"      Cnattingius S, Nordstr&ouml;m ML. Maternal smoking and feto-infant mortality: biological pathways and public health significance. Acta Paediatr 1996; 85:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/57\">",
"      Cnattingius S, Forman MR, Berendes HW, Isotalo L. Delayed childbearing and risk of adverse perinatal outcome. A population-based study. JAMA 1992; 268:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/58\">",
"      Ahlborg G Jr, Bodin L. Tobacco smoke exposure and pregnancy outcome among working women. A prospective study at prenatal care centers in Orebro County, Sweden. Am J Epidemiol 1991; 133:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/59\">",
"      Ekwo EE, Gosselink CA, Woolson R, Moawad A. Risks for premature rupture of amniotic membranes. Int J Epidemiol 1993; 22:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/60\">",
"      Hadley CB, Main DM, Gabbe SG. Risk factors for preterm premature rupture of the fetal membranes. Am J Perinatol 1990; 7:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/61\">",
"      Harger JH, Hsing AW, Tuomala RE, et al. Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study. Am J Obstet Gynecol 1990; 163:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/62\">",
"      Spinillo A, Nicola S, Piazzi G, et al. Epidemiological correlates of preterm premature rupture of membranes. Int J Gynaecol Obstet 1994; 47:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/63\">",
"      Williams MA, Mittendorf R, Stubblefield PG, et al. Cigarettes, coffee, and preterm premature rupture of the membranes. Am J Epidemiol 1992; 135:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/64\">",
"      Cnattingius S. Maternal age modifies the effect of maternal smoking on intrauterine growth retardation but not on late fetal death and placental abruption. Am J Epidemiol 1997; 145:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/65\">",
"      Raymond EG, Mills JL. Placental abruption. Maternal risk factors and associated fetal conditions. Acta Obstet Gynecol Scand 1993; 72:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/66\">",
"      Ananth CV, Savitz DA, Luther ER. Maternal cigarette smoking as a risk factor for placental abruption, placenta previa, and uterine bleeding in pregnancy. Am J Epidemiol 1996; 144:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/67\">",
"      Chelmow D, Andrew DE, Baker ER. Maternal cigarette smoking and placenta previa. Obstet Gynecol 1996; 87:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/68\">",
"      Kramer MD, Taylor V, Hickok DE, et al. Maternal smoking and placenta previa. Epidemiology 1991; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/69\">",
"      Handler AS, Mason ED, Rosenberg DL, Davis FG. The relationship between exposure during pregnancy to cigarette smoking and cocaine use and placenta previa. Am J Obstet Gynecol 1994; 170:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/70\">",
"      Monica G, Lilja C. Placenta previa, maternal smoking and recurrence risk. Acta Obstet Gynecol Scand 1995; 74:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/71\">",
"      McMahon MJ, Li R, Schenck AP, et al. Previous cesarean birth. A risk factor for placenta previa? J Reprod Med 1997; 42:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/72\">",
"      Zhang J, Fried DB. Relationship of maternal smoking during pregnancy to placenta previa. Am J Prev Med 1992; 8:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/73\">",
"      Li CQ, Windsor RA, Perkins L, et al. The impact on infant birth weight and gestational age of cotinine-validated smoking reduction during pregnancy. JAMA 1993; 269:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/74\">",
"      Cnattingius S, Forman MR, Berendes HW, et al. Effect of age, parity, and smoking on pregnancy outcome: a population-based study. Am J Obstet Gynecol 1993; 168:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/75\">",
"      Shiono PH, Klebanoff MA, Rhoads GG. Smoking and drinking during pregnancy. Their effects on preterm birth. JAMA 1986; 255:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/76\">",
"      Peacock JL, Bland JM, Anderson HR. Preterm delivery: effects of socioeconomic factors, psychological stress, smoking, alcohol, and caffeine. BMJ 1995; 311:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/77\">",
"      Seidman DS, Ever-Hadani P, Gale R. Effect of maternal smoking and age on congenital anomalies. Obstet Gynecol 1990; 76:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/78\">",
"      Malloy MH, Kleinman JC, Bakewell JM, et al. Maternal smoking during pregnancy: no association with congenital malformations in Missouri 1980-83. Am J Public Health 1989; 79:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/79\">",
"      Shiono PH, Klebanoff MA, Berendes HW. Congenital malformations and maternal smoking during pregnancy. Teratology 1986; 34:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/80\">",
"      Van den Eeden SK, Karagas MR, Daling JR, Vaughan TL. A case-control study of maternal smoking and congenital malformations. Paediatr Perinat Epidemiol 1990; 4:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/81\">",
"      Werler MM. Teratogen update: smoking and reproductive outcomes. Teratology 1997; 55:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/82\">",
"      Wyszynski DF, Duffy DL, Beaty TH. Maternal cigarette smoking and oral clefts: a meta-analysis. Cleft Palate Craniofac J 1997; 34:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/83\">",
"      Lorente C, Cordier S, Goujard J, et al. Tobacco and alcohol use during pregnancy and risk of oral clefts. Occupational Exposure and Congenital Malformation Working Group. Am J Public Health 2000; 90:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/84\">",
"      K&auml;ll&eacute;n K. Maternal smoking and orofacial clefts. Cleft Palate Craniofac J 1997; 34:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/85\">",
"      Shaw GM, Wasserman CR, Lammer EJ, et al. Orofacial clefts, parental cigarette smoking, and transforming growth factor-alpha gene variants. Am J Hum Genet 1996; 58:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/86\">",
"      Christensen K, Olsen J, N&oslash;rgaard-Pedersen B, et al. Oral clefts, transforming growth factor alpha gene variants, and maternal smoking: a population-based case-control study in Denmark, 1991-1994. Am J Epidemiol 1999; 149:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/87\">",
"      Meyer KA, Williams P, Hernandez-Diaz S, Cnattingius S. Smoking and the risk of oral clefts: exploring the impact of study designs. Epidemiology 2004; 15:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/88\">",
"      Ramirez D, Lammer EJ, Iovannisci DM, et al. Maternal smoking during early pregnancy, GSTP1 and EPHX1 variants, and risk of isolated orofacial clefts. Cleft Palate Craniofac J 2007; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/89\">",
"      Shi M, Christensen K, Weinberg CR, et al. Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants. Am J Hum Genet 2007; 80:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/90\">",
"      Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992; 45:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/91\">",
"      Yuan P, Okazaki I, Kuroki Y. Anal atresia: effect of smoking and drinking habits during pregnancy. Jpn J Hum Genet 1995; 40:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/92\">",
"      K&auml;ll&eacute;n K. Maternal smoking during pregnancy and limb reduction malformations in Sweden. Am J Public Health 1997; 87:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/93\">",
"      Czeizel AE, Kodaj I, Lenz W. Smoking during pregnancy and congenital limb deficiency. BMJ 1994; 308:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/94\">",
"      Lee LJ, Lupo PJ. Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis. Pediatr Cardiol 2013; 34:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/95\">",
"      Man LX, Chang B. Maternal cigarette smoking during pregnancy increases the risk of having a child with a congenital digital anomaly. Plast Reconstr Surg 2006; 117:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/96\">",
"      Slickers JE, Olshan AF, Siega-Riz AM, et al. Maternal body mass index and lifestyle exposures and the risk of bilateral renal agenesis or hypoplasia: the National Birth Defects Prevention Study. Am J Epidemiol 2008; 168:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/97\">",
"      Ever-Hadani P, Seidman DS, Manor O, Harlap S. Breast feeding in Israel: maternal factors associated with choice and duration. J Epidemiol Community Health 1994; 48:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/98\">",
"      Letson GW, Rosenberg KD, Wu L. Association between smoking during pregnancy and breastfeeding at about 2 weeks of age. J Hum Lact 2002; 18:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/99\">",
"      Horta BL, Kramer MS, Platt RW. Maternal smoking and the risk of early weaning: a meta-analysis. Am J Public Health 2001; 91:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/100\">",
"      Giglia R, Binns CW, Alfonso H. Maternal cigarette smoking and breastfeeding duration. Acta Paediatr 2006; 95:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/101\">",
"      Vio F, Salazar G, Infante C. Smoking during pregnancy and lactation and its effects on breast-milk volume. Am J Clin Nutr 1991; 54:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/102\">",
"      Agostoni C, Marangoni F, Grandi F, et al. Earlier smoking habits are associated with higher serum lipids and lower milk fat and polyunsaturated fatty acid content in the first 6 months of lactation. Eur J Clin Nutr 2003; 57:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/103\">",
"      Hill PD, Aldag JC. Smoking and breastfeeding status. Res Nurs Health 1996; 19:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/104\">",
"      Mennella JA, Yourshaw LM, Morgan LK. Breastfeeding and smoking: short-term effects on infant feeding and sleep. Pediatrics 2007; 120:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/105\">",
"      Mascola MA, Van Vunakis H, Tager IB, et al. Exposure of young infants to environmental tobacco smoke: breast-feeding among smoking mothers. Am J Public Health 1998; 88:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/106\">",
"      Malloy MH, Kleinman JC, Land GH, Schramm WF. The association of maternal smoking with age and cause of infant death. Am J Epidemiol 1988; 128:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/107\">",
"      Skorge TD, Eagan TM, Eide GE, et al. The adult incidence of asthma and respiratory symptoms by passive smoking in uterus or in childhood. Am J Respir Crit Care Med 2005; 172:61.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetrics and Gynecology. Smoking and Women's Health: ACOG Educational Bulletin, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/109\">",
"      Committee opinion no. 471: Smoking cessation during pregnancy. Obstet Gynecol 2010; 116:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/110\">",
"      Weissman MM, Warner V, Wickramaratne PJ, Kandel DB. Maternal smoking during pregnancy and psychopathology in offspring followed to adulthood. J Am Acad Child Adolesc Psychiatry 1999; 38:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/111\">",
"      Wakschlag LS, Lahey BB, Loeber R, et al. Maternal smoking during pregnancy and the risk of conduct disorder in boys. Arch Gen Psychiatry 1997; 54:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/112\">",
"      Kandel DB, Wu P, Davies M. Maternal smoking during pregnancy and smoking by adolescent daughters. Am J Public Health 1994; 84:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/113\">",
"      Environmental tobacco smoke: a hazard to children. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1997; 99:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/114\">",
"      Gilman SE, Gardener H, Buka SL. Maternal smoking during pregnancy and children's cognitive and physical development: a causal risk factor? Am J Epidemiol 2008; 168:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/115\">",
"      Kenner T, Einspieler C, Haidmayer R. Re: \"Sudden infant death syndrome: risk factor profiles for distinct subgroups\". Am J Epidemiol 1999; 149:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/116\">",
"      Mitchell EA, Tuohy PG, Brunt JM, et al. Risk factors for sudden infant death syndrome following the prevention campaign in New Zealand: a prospective study. Pediatrics 1997; 100:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/117\">",
"      Alm B, Milerad J, Wennergren G, et al. A case-control study of smoking and sudden infant death syndrome in the Scandinavian countries, 1992 to 1995. The Nordic Epidemiological SIDS Study. Arch Dis Child 1998; 78:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/118\">",
"      Schellscheidt J, Oyen N, Jorch G. Interactions between maternal smoking and other prenatal risk factors for sudden infant death syndrome (SIDS). Acta Paediatr 1997; 86:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/119\">",
"      Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/120\">",
"      Manson JE, Ajani UA, Liu S, et al. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000; 109:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/121\">",
"      Montgomery SM, Ekbom A. Smoking during pregnancy and diabetes mellitus in a British longitudinal birth cohort. BMJ 2002; 324:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/122\">",
"      Jensen TK, J&oslash;rgensen N, Punab M, et al. Association of in utero exposure to maternal smoking with reduced semen quality and testis size in adulthood: a cross-sectional study of 1,770 young men from the general population in five European countries. Am J Epidemiol 2004; 159:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/123\">",
"      Wilcox AJ, Baird DD, Weinberg CR. Do women with childhood exposure to cigarette smoking have increased fecundability? Am J Epidemiol 1989; 129:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/124\">",
"      Lutterodt MC, S&oslash;rensen KP, Larsen KB, et al. The number of oogonia and somatic cells in the human female embryo and fetus in relation to whether or not exposed to maternal cigarette smoking. Hum Reprod 2009; 24:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/125\">",
"      Mamsen LS, Lutterodt MC, Andersen EW, et al. Cigarette smoking during early pregnancy reduces the number of embryonic germ and somatic cells. Hum Reprod 2010; 25:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/126\">",
"      Ye X, Skjaerven R, Basso O, et al. In utero exposure to tobacco smoke and subsequent reduced fertility in females. Hum Reprod 2010; 25:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/127\">",
"      Ayer JG, Belousova E, Harmer JA, et al. Maternal cigarette smoking is associated with reduced high-density lipoprotein cholesterol in healthy 8-year-old children. Eur Heart J 2011; 32:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/128\">",
"      Geerts CC, Bots ML, van der Ent CK, et al. Parental smoking and vascular damage in their 5-year-old children. Pediatrics 2012; 129:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/129\">",
"      Ng SP, Silverstone AE, Lai ZW, Zelikoff JT. Effects of prenatal exposure to cigarette smoke on offspring tumor susceptibility and associated immune mechanisms. Toxicol Sci 2006; 89:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/130\">",
"      Pavlidis N. Lung cancer during pregnancy: an emerging issue. Lung Cancer 2008; 59:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/131\">",
"      Castles A, Adams EK, Melvin CL, et al. Effects of smoking during pregnancy. Five meta-analyses. Am J Prev Med 1999; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/132\">",
"      Mehendale R, Hibbard J, Fazleabas A, Leach R. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am J Obstet Gynecol 2007; 197:363.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/133\">",
"      Tong, VT, Jones, JR, Dietz, PM, et al. Trends in Smoking Before, During, and After Pregnancy --- Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 Sites, 2000--2005. MMWR 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/134\">",
"      Cnattingius S, Lindmark G, Meirik O. Who continues to smoke while pregnant? J Epidemiol Community Health 1992; 46:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/135\">",
"      Fingerhut LA, Kleinman JC, Kendrick JS. Smoking before, during, and after pregnancy. Am J Public Health 1990; 80:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/136\">",
"      Orleans CT, Barker DC, Kaufman NJ, Marx JF. Helping pregnant smokers quit: meeting the challenge in the next decade. Tob Control 2000; 9 Suppl 3:III6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/137\">",
"      M&aacute;s R, Escrib&agrave; V, Colomer C. Who quits smoking during pregnancy? Scand J Soc Med 1996; 24:102.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation.: U. S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/139\">",
"      Valb&oslash; A, Nylander G. Smoking cessation in pregnancy. Intervention among heavy smokers. Acta Obstet Gynecol Scand 1994; 73:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/140\">",
"      Woodby LL, Windsor RA, Snyder SW, et al. Predictors of smoking cessation during pregnancy. Addiction 1999; 94:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/141\">",
"      Stewart DE, Streiner DL. Cigarette smoking during pregnancy. Can J Psychiatry 1995; 40:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/142\">",
"      Adams MM, Brogan DJ, Kendrick JS, et al. Smoking, pregnancy, and source of prenatal care: results from the Pregnancy Risk Assessment Monitoring System. The Pregnancy Risk Assessment Monitoring System Working Group. Obstet Gynecol 1992; 80:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/143\">",
"      Wewers ME, Salsberry PJ, Ferketich AK, et al. Risk factors for smoking in rural women. J Womens Health (Larchmt) 2012; 21:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/144\">",
"      Dolan-Mullen P, Ram&iacute;rez G, Groff JY. A meta-analysis of randomized trials of prenatal smoking cessation interventions. Am J Obstet Gynecol 1994; 171:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/145\">",
"      Lumley J, Chamberlain C, Dowswell T, et al. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2009; :CD001055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/146\">",
"      Filion KB, Abenhaim HA, Mottillo S, et al. The effect of smoking cessation counselling in pregnant women: a meta-analysis of randomised controlled trials. BJOG 2011; 118:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/147\">",
"      Myung SK, Ju W, Jung HS, et al. Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta-analysis. BJOG 2012; 119:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/148\">",
"      Chan B, Einarson A, Koren G. Effectiveness of bupropion for smoking cessation during pregnancy. J Addict Dis 2005; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/149\">",
"      Hotham ED, Atkinson ER, Gilbert AL. Focus groups with pregnant smokers: barriers to cessation, attitudes to nicotine patch use and perceptions of cessation counselling by care providers. Drug Alcohol Rev 2002; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/150\">",
"      Melvin CL, Dolan-Mullen P, Windsor RA, et al. Recommended cessation counselling for pregnant women who smoke: a review of the evidence. Tob Control 2000; 9 Suppl 3:III80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/151\">",
"      Oncken C, Dornelas E, Greene J, et al. Nicotine gum for pregnant smokers: a randomized controlled trial. Obstet Gynecol 2008; 112:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/152\">",
"      The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996; 275:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/153\">",
"      Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/154\">",
"      Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA 1991; 266:3174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/155\">",
"      Xiao D, Huang X, Yang S, Zhang L. Direct effects of nicotine on contractility of the uterine artery in pregnancy. J Pharmacol Exp Ther 2007; 322:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/156\">",
"      Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatr 2008; 97:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/157\">",
"      Swamy GK, Roelands JJ, Peterson BL, et al. Predictors of adverse events among pregnant smokers exposed in a nicotine replacement therapy trial. Am J Obstet Gynecol 2009; 201:354.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/158\">",
"      Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2001; :CD000146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/159\">",
"      Coleman T, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2012; 9:CD010078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/160\">",
"      Coleman T, Cooper S, Thornton JG, et al. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med 2012; 366:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/161\">",
"      Pollak KI, Oncken CA, Lipkus IM, et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med 2007; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/162\">",
"      Hegaard HK, Kjaergaard H, M&oslash;ller LF, et al. Multimodal intervention raises smoking cessation rate during pregnancy. Acta Obstet Gynecol Scand 2003; 82:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/163\">",
"      Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685.",
"     </a>",
"    </li>",
"    <li>",
"     Fiore, MC, Bailey, WC, Cohen, SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville: U.S. Department of Health and Human Services. Public Health Service, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/165\">",
"      Tran T, Reeder A, Funke L, Richmond N. Association Between Smoking Cessation Interventions During Prenatal Care and Postpartum Relapse: Results from 2004 to 2008 Multi-State PRAMS Data. Matern Child Health J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/166\">",
"      Harmer C, Memon A. Factors Associated With Smoking Relapse in the Postpartum Period: An Analysis of the Child Health Surveillance System Data in Southeast England. Nicotine Tob Res 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/167\">",
"      Lauria L, Lamberti A, Grandolfo M. Smoking behaviour before, during, and after pregnancy: the effect of breastfeeding. ScientificWorldJournal 2012; 2012:154910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/168\">",
"      Kendzor DE, Businelle MS, Costello TJ, et al. Breast feeding is associated with postpartum smoking abstinence among women who quit smoking due to pregnancy. Nicotine Tob Res 2010; 12:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/169\">",
"      McBride CM, Pirie PL, Curry SJ. Postpartum relapse to smoking: a prospective study. Health Educ Res 1992; 7:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/170\">",
"      Barnet B, Duggan AK, Wilson MD, Joffe A. Association between postpartum substance use and depressive symptoms, stress, and social support in adolescent mothers. Pediatrics 1995; 96:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/171\">",
"      Borrelli B, Bock B, King T, et al. The impact of depression on smoking cessation in women. Am J Prev Med 1996; 12:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/172\">",
"      Rausch JL, Nichinson B, Lamke C, Matloff J. Influence of negative affect on smoking cessation treatment outcome: a pilot study. Br J Addict 1990; 85:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/173\">",
"      Van't Hof SM, Wall MA, Dowler DW, Stark MJ. Randomised controlled trial of a postpartum relapse prevention intervention. Tob Control 2000; 9 Suppl 3:III64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/174\">",
"      DiClemente CC, Dolan-Mullen P, Windsor RA. The process of pregnancy smoking cessation: implications for interventions. Tob Control 2000; 9 Suppl 3:III16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/175\">",
"      Levitt C, Shaw E, Wong S, et al. Systematic review of the literature on postpartum care: effectiveness of interventions for smoking relapse prevention, cessation, and reduction in postpartum women. Birth 2007; 34:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/176\">",
"      Leonardi-Bee J, Britton J, Venn A. Secondhand smoke and adverse fetal outcomes in nonsmoking pregnant women: a meta-analysis. Pediatrics 2011; 127:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/177\">",
"      Crane JM, Keough M, Murphy P, et al. Effects of environmental tobacco smoke on perinatal outcomes: a retrospective cohort study. BJOG 2011; 118:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/178\">",
"      Salmasi G, Grady R, Jones J, et al. Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta Obstet Gynecol Scand 2010; 89:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/179\">",
"      Leonardi-Bee J, Smyth A, Britton J, Coleman T. Environmental tobacco smoke and fetal health: systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2008; 93:F351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/53/27482/abstract/180\">",
"      Cox B, Martens E, Nemery B, et al. Impact of a stepwise introduction of smoke-free legislation on the rate of preterm births: analysis of routinely collected birth data. BMJ 2013; 346:f441.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4803 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27482=[""].join("\n");
var outline_f26_53_27482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFYING MATERNAL TOBACCO USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subfertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Low birth weight and small for gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Spontaneous pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Stillbirth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Placental abruption/placenta previa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7469948\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Postnatal morbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Maternal health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SMOKING CESSATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nicotine replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bupropion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1260650532\">",
"      Varenicline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Conclusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POSTPARTUM RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SECONDHAND SMOKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4803|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 1\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/40/14990\" title=\"table 2\">",
"      Smoking cessation in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=related_link\">",
"      Control of secondhand smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=related_link\">",
"      Patient information: Secondhand smoke: Risks to children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/60/43969?source=related_link\">",
"      Patient information: Smoking in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_53_27483="Administering positive pressure";
var content_f26_53_27483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of the different methods for administering positive airway pressure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode of positive pressure ventilation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        CPAP",
"       </td>",
"       <td>",
"        Inexpensive",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Lack of inspiratory pressure support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Widely available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Bi-level",
"       </td>",
"       <td>",
"        Widely available",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Tidal volume may may be limited by patient-related factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can provide inspiratory pressure support to augment tidal volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leak tolerant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Volume-cycled",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Can set specific respiratory parameters",
"       </td>",
"       <td>",
"        More expensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less widely available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less well-tolerated than pressure support devices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leaks lead to loss of tidal volume",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27483=[""].join("\n");
var outline_f26_53_27483=null;
var title_f26_53_27484="Emetogenicity oral chemotherapy agents";
var content_f26_53_27484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Emetogenic potential of oral antineoplastic agents*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Degree of emetogenicity (incidence)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High (&gt;90 percent)",
"       </td>",
"       <td>",
"        <p>",
"         Hexamethylmelamine",
"        </p>",
"        <p>",
"         Procarbazine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Moderate (30 to 90 percent)",
"       </td>",
"       <td>",
"        <p>",
"         Altretamine",
"        </p>",
"        <p>",
"         Bosutinib",
"        </p>",
"        <p>",
"         Busulfan (&ge;4 mg/day)",
"        </p>",
"        <p>",
"         Crizotinib",
"        </p>",
"        <p>",
"         Cyclophosphamide",
"        </p>",
"        <p>",
"         Imatinib",
"        </p>",
"        <p>",
"         Lomustine",
"        </p>",
"        <p>",
"         Temozolomide",
"        </p>",
"        <p>",
"         Tretinoin",
"        </p>",
"        <p>",
"         Vandetanib",
"        </p>",
"        <p>",
"         Vinorelbine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Low (10 to 30 precent)",
"       </td>",
"       <td>",
"        <p>",
"         Axitinib",
"        </p>",
"        <p>",
"         Bexarotene",
"        </p>",
"        <p>",
"         Capecitabine",
"        </p>",
"        <p>",
"         Cetuximab",
"        </p>",
"        <p>",
"         Dasatinib",
"        </p>",
"        <p>",
"         Estramustine",
"        </p>",
"        <p>",
"         Etoposide",
"        </p>",
"        <p>",
"         Everolimus",
"        </p>",
"        <p>",
"         Fludarabine",
"        </p>",
"        <p>",
"         Lapatinib",
"        </p>",
"        <p>",
"         Lenalidomide",
"        </p>",
"        <p>",
"         Nilotinib",
"        </p>",
"        <p>",
"         Panitumumab",
"        </p>",
"        <p>",
"         Pazopanib",
"        </p>",
"        <p>",
"         Sunitinib",
"        </p>",
"        <p>",
"         Tegafur uracil",
"        </p>",
"        <p>",
"         Thalidomide",
"        </p>",
"        <p>",
"         Topotecan",
"        </p>",
"        <p>",
"         Vemurafenib",
"        </p>",
"        <p>",
"         Vorinostat",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Minimal (&lt;10 percent)",
"       </td>",
"       <td>",
"        <p>",
"         6-Thioguanine",
"        </p>",
"        <p>",
"         Chlorambucil",
"        </p>",
"        <p>",
"         Erlotinib",
"        </p>",
"        <p>",
"         Gefitinib",
"        </p>",
"        <p>",
"         Hydroxyurea",
"        </p>",
"        <p>",
"         Melphalan (L-phenylalanine mustard)",
"        </p>",
"        <p>",
"         Methotrexate",
"        </p>",
"        <p>",
"         Regorafenib",
"        </p>",
"        <p>",
"         Sorafenib",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Considerable uncertainty prevails for the emetogenic risk of oral agents.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 Suppl:v232. Copyright &copy; 2010 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27484=[""].join("\n");
var outline_f26_53_27484=null;
var title_f26_53_27485="Survival cervical adenocarcinoma versus SCC";
var content_f26_53_27485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of survival for cervical adenocarcinoma and squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author, year",
"        <sup>",
"         [ref]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients (n)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        5-year survival (percent)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        p-Value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        SCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Hopkins et al, 1991",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        959 (203 AC, 756 SCC)",
"       </td>",
"       <td rowspan=\"3\">",
"        Pelvic RT +/- radical hysterectomy, pelvic, and PA nodes for stage IB",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        &lt;0.0001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Eifel et al, 1995",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        1767 (229 AC, 1538 SCC)",
"       </td>",
"       <td>",
"        Pelvic RT +/- extrafascial hysterectomy",
"       </td>",
"       <td>",
"        IB",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        &lt;0.01",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Chen et al, 1999",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td rowspan=\"5\">",
"        3678 (302 AC, 3376 SCC)",
"       </td>",
"       <td rowspan=\"2\">",
"        Stage IB-IIA: radical hysterectomy, pelvic nodes or RT",
"       </td>",
"       <td>",
"        Overall",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        0.0009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        0.0039",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stage IIB-IV: RT +/- CT",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        0.0103",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lai et al, 1999",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        891 (134 AC, 757 SCC)",
"       </td>",
"       <td>",
"        Radical hysterectomy, pelvic nodes +/- adjuvant RT",
"       </td>",
"       <td>",
"        IB &amp; II",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        0.0136",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Irie et al, 2000",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        255 (57 AC, 198 SCC)",
"       </td>",
"       <td rowspan=\"3\">",
"        Radical hysterectomy, pelvic nodes +/- adjuvant RT",
"       </td>",
"       <td>",
"        Overall",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        0.0034",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IB",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        0.0007",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: adenocarcinoma; SCC: squamous cell carcinoma; RT: radiation therapy; CT: chemotherapy; PA: para-aortic; NS: not significant; ref: reference.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991; 77:912.",
"       </li>",
"       <li>",
"        Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage 1B cervical carcinoma. Gynecol Oncol 1995; 59:38.",
"       </li>",
"       <li>",
"        Chen RJ, Lin YH, Chen CA, et al. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999; 73:184.",
"       </li>",
"       <li>",
"        Lai CH, Hsueh S, Hong JH, et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer 1999; 9:28.",
"       </li>",
"       <li>",
"        Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000; 26:464.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced from: Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010; 116:140. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27485=[""].join("\n");
var outline_f26_53_27485=null;
var title_f26_53_27486="Causes of cardiomyopathy I";
var content_f26_53_27486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of cardiomyopathy-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diptheria*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Typhoid fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatic fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Scarlet fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meningococcal*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pneumococcal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gonococcal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tetanus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meliodosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tularemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pertussis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Spirochetal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leptospirosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lyme disease*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Rickettsial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Typhus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rocky mountain spotted fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Q fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Parvovirus B19*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Human herpesvirus 6*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Poliomyelitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Influenza*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mumps*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubella*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubeola*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Variola*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Varicella*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epstein-Barr*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral (cont'd)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coxsackievirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echovirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytomegalovirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rabies*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mycoplasma*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psittacosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Herpes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Encephalitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arboviruses*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mycotic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Actinomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Blastomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Moniliasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aspergiliosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histoplasmosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coccidiomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cryptococcosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Protozoal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            South American",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            trypanosomiasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            African trypanosomiasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toxoplasmosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amebiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leishmaniasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Balantidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcosporidiosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Helminthic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trichiniasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echinococcosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Helminthic (cont'd)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Schistosomiasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ascariasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Heterophydiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Filariasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Paragonimiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Strongyloidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cysticercosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Visceral larva migrans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxins and drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adriamycin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amphetamine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antimony",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arsenic*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon tetrachloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Catecholamines*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cobalt*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cocaine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclophosphamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Emetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethyl alcohol*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methysergide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenothiazine drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phosphorus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Zidovudine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation*&bull;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Conditions that may manifest clinically as dilated cardiomyopathy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Conditions that may manifest clinically as restrictive cardiomyopathy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Abelmann, WH. Introduction to Atlas of Heart Diseases, Vol. II: Cardiomyopathies, Myocarditis and Pericardial disease, Abelmann, WH (Ed), Current Medicine, Philadelphia, 1995, p. 1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27486=[""].join("\n");
var outline_f26_53_27486=null;
var title_f26_53_27487="Clinical phases for AKI";
var content_f26_53_27487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Clinical phases of acute kidney injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sutton, TA, Fisher, CJ, Molitoris, BA, et al. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62:1539. Copyright &copy;2002 Macmillan Publishers Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_53_27487=[""].join("\n");
var outline_f26_53_27487=null;
